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 INTRODUCTION AND BACKGROUND : 
The Enterococci are normal commensal microorganisms , 
considered  virtually as  harmless bacteria. Normally it is a part of the 
indigenous flora of the intestinal tract, oral cavity and genitourinary tract 
of humans and animals. They have long  been known as` Faecal 
Streptococci’ , a potential human pathogen, capable of causing a variety 
of  infections in the community as well as  in the hospital. During the 
past few decades , they have emerged  as an important  nosocomial 
pathogen exhibiting multiple drug resistance, contributing significantly 
to patient morbidity and mortality44.  It is due to their  ability to survive 
and disseminate in hospital environment which is mainly attributed to 
their intrinsic resistance to many of the commonly used antibiotics and  
especially to their ability to acquire resistance to most of the currently 
available antibiotics either by mutation or through transfer of mobile 
genetic elements carrying resistance genes/ virulence factors11. 
They cause serious infections like endocarditis and bacteremia, 
meningitis , intra abdominal and pelvic infections, burn and surgical site 
wound infections in both immune-competent and immune-compromised 
individuals. They pose a special risk in causing infection of the catheters 
and various other implanted medical devices in critically ill patients  and  
also cause late onset sepsis , pneumonia and meningitis in neonates7. In 
the 2006-2007 report from Centers for Disease Control and Prevention 
(CDC) Enterococci  account for about 12% of  health care associated 
infections (HAI) and  ranks third most common  multi-drug resistant 
pathogen causing HAI12.  Since the intial report of emergence of  
Vancomycin resistant Enterococci (VRE) reported  in United kingdom 
and France , there have been  increasing incidence of VRE being 
reported  from various other countries like Australia, Canada, Germany, 
Malaysia, Spain  and United States 11. 
Because of their intrinsic and acquired resistance to the commonly 
used broad spectrum antibiotics, clinician are left with fewer options for 
treatment of VRE infections especially in debilitated and seriously ill 
patients. The alarming thing is the increasing evidence of potential risk 
of transfer of Vancomycin resistance gene from VRE to various Gram- 
positive  microorganisms especially Staphylococcus aureus through 
conjugative plasmids, which worsens the scenario further11. Hence it is 
an essential part of the surveillance system of each and every hospital 
setup to monitor continuously such VRE infections and to assess the 
antibiotic susceptibility pattern of VRE isolates. Assessment of  the 
prevalence and changing trends of VRE infections  are of immense help 
in planning infection control measures which should be implemented in 
the hospital and also in the community to reduce the mortality and 
morbidity caused by these VRE infections. In  view of the above 
perspective, the present study is carried out in our tertiary care hospital 
in Chennai, South India to assess the prevalence  and the antibiotic 
susceptibility pattern of Vancomycin Resistant Enterococci  in our 
region.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS: 
       To study the prevalence of  vancomycin  resistance among the 
Enterococcal  species isolated from various clinical samples  such as 
urine, blood, pus,  tissue fluids and feces obtained  from the  patients  of 
a tertiary care hospital. 
OBJECTIVES: 
1. Isolation and identification of Enterococci  from various clinical 
samples by standard techniques. 
2. Characterization of the Enterococcal   isolates to  the  species 
level. 
3. Assessment of the Antibiotic susceptibility pattern of these 
isolates by standard techniques. 
4. To study the specific resistance mechanisms like resistance to 
penicillins, High level Aminoglycoside resistance (HLAR) by 
standard techniques. 
5. To study the vancomycin resistance among the Enterococcal 
isolates and its characterization by standard phenotypic methods. 
6. To assess the prevalence of  VanA genotype among the 
Vancomycin Resistant Enterococci  by Polymease Chain Reaction 
(PCR)assay for VanA gene.  
REVIEW OF LITERATURE: 
DESCRIPTION OF GENUS: 
  The Enterococci were mentioned first in French literature in 1899 
as “enterococque” and isolated from a case of endocarditis  in the same 
year6,7. It was initially designated as “Micrococcus  zymogenes” and  
from 1906 onwards  as “Streptococcus faecalis”  and later in 1984 , 
assigned  a separate genus “Enterococcus”based on DNA hybridization 
studies. Around 18 species  have been identified from clinical isolates, 
the  predominant one being E.faecalis( 80 to 90%) and E.faecium (5 
to10%)7,11 . Other species like E.gallinarum.E.durans,E.hirae,E.avium   
are less frequently isolated7.    
• Enterococci are  gram-positive cocci , oval in shape, arranged as  
single cell, pairs ,short chains and rarely even long chains. 
• They are non-motile (except E. gallinarum, E.casseliflavus) and 
non capsulated16. 
• They are facultative anaerobes producing lactic acid but gas is not 
produced.  
• They are generally catalase negative (few strains of E.faecalis 
produce weak effervescence when grown on blood agar) and are 
usually - hemolytic or non-hemolytic. Some cultures of 
E.faecalis are -hemolytic on human, horse and rabbit blood agar 
but non-hemolytic on sheep blood. 
• About 80% of  Enterococci  react with Lancefield group D 
antigen28.  
• They are able to grow at temperature between 10ºC and 45ºC, 
showing optimum growth at35 to 37ºC. 
• On blood agar after 24 hrs growth, they produce white to grey 
coloured  colonies, 1to 2mm  diameter and on MacConkey agar 
0.5- 1mm  majenta pink coloured colonies are produced16.  
• Majority of them grow in broth containing 6.5% NaCl, at pH 9.6, 
and survive heating at 60ºC for 30 minutes 11,37 .  
• They hydrolyse  esculin in the presence of 40% bile (Bile esculin 
test). 
• They hydrolyse  L-pyrrolidonyl –-naphthylamide (PYR) to 
produce pyrolidonyl arylamidase  and also hydrolyse  leucine –-
naphthylamide  producing leucine aminopeptidase (LAP). 
• Some species  produce pigment(yellowish) (E.casseliflavus, 
Emundtii, E.pallens, E.sulfureus and E. gilvus). 
•  Enterococci  don’t produce cytochrome oxidase enzymes45  
• Most of the Enteococcial species except a few, react with 
Accuprobe Enterococcus  genetic probe and this can be used  to 
confirm  an unknown strain as Enterococcus. 
GENOME: 
The genome size is about 2 to 3.5 Mb and the G+ C content is 32 
to 44 mol %. The genome of E.faecalis V583, the first vancomycin 
resistant clinical isolate from United States is completely sequenced  and  
is useful in various research purposes 45. The genome of  > 80 
enterococcal  strains has been sequenced 7. The genetic diversity of 
enterococci is due the acquisition of mobile DNA like plasmids, 
transposons and phages and also a result of recombination of “ core” 
genomes. The medically important E.faecium  harbors  an accessory 
genome into which exogenous genetic elements like Phage DNA are 
incorporated7 .It also harbors  pathogenicity island11,21,  which is a large 
genetic element carrying virulence associated genes and plasmids with 
antibiotic resistant determinants. 
EPIDEMIOLOGY: 
Enterococci are distributed widely in nature as they can be found 
in soil, plants, water, food, animals, birds and reptiles. In humans, they 
are predominant commensals  of  gastrointestinal and biliary tract and  
found  in less numbers in genitourinary tract, oral cavity and perineal 
skin28,45. The prevalence of different Enterococcal species is influenced 
by host factors, age, diet, underlying disease and prior antimicrobial 
therapy. The most abundant species colonizing the gastrointestinal tract 
is E.faecalis and others like E.faecium, E.casseliflavus, E.durans, 
E.gallinarum in variable proportions 7,45. The gastrointestinal tract 
represents the endogenous  source/reservoir for disease causing  strains , 
they may migrate from here to infection site and also disseminate to 
other hosts and to the environment 45. They are used as indicators of 
hygienic quality and fecal contamination of food, milk and drinking 
water45. 
The predominant species encountered in nosocomial  infections is 
E.faecalis, however E.faecium is on the rise in the past few decades. 
Now-a-days E.faecium is being isolated as common as E.faecalis in 
hospital associated infections7.  About 30% of  enterococcal infections 
are caused by VRE, with E.faecium being the commonest isolate (>90%) 
6
. 
PATHOGENESIS: 
Since Enterococci are opportunistic pathogens , these infections 
may  arise from translocation of  Enterococcal cells from the site of  
colonization of the gastrointestinal system to other sites in host and to 
the hospital environment6. However the pathogenesis of Enterococcal 
infections is only poorly understood. The source could be  either 
endogenous or exogenous , however studies show that there may exist a 
subset of virulent lineage with greater ability to cause disease and often 
responsible for outbreaks and  infections of epidemic proportions. 
Acquisition of new traits ( pathogenecity island, virulence 
associated genes,multi-drug resistance etc..) and their intrinsic resistance 
to the commonly used antibiotics allow the bacterium to overcome host  
defense mechanisms. These traits along with the acquired  antimicrobial 
resistance differentiates the virulent pathogenic strains from the 
commensals.   These along with the changed dynamics  of  host –
commensal relationships like diminished host immunity, host injury and 
broad spectrum antibiotic use, promote colonization of new niches 
favoring infections and its dissemination to other tissues and 
environment45.In particular use of drugs that are excreted in bile and 
broad spectrum antibiotics like cephalosporins (active against anaerobes 
and gram negative bacteria)  eradicate the competing components of  
intestinal flora and also cause suppression of important immunological 
signals(e.g lectin RegIII) that keep the Enterococi in low numbers 
normally. Thus  the virulent strains exhibit survival advantage over 
others to persist for longer periods in the host and environment and play 
a prominent role as nosocomial pathogens. The important factor that 
Enterococci can transfer the resistant determinants to other Gram 
positive bacteria 6,11, further increases their clinical significance. 
VIRULENCE FACTORS:  
The potential virulence factors( Enterococcal secreted factors , 
Enterococcal surface components) identified in Enterococcal isolates  
and  proposed  to  play a role in pathogenesis  are as follows6,7,11,28,45 
Enterococcal secereted factors:  
  Cytolysin /hemolysin- a heterodimeric toxin  secreted by some 
strains of E.faecalis lyses human, rabbit, equine and bovine 
erythrocytes (but not sheep rbcs) and  polymorphonuclear 
leucocytes and macrophages, playing significant role in 
endocarditis and rabbit endophthalmitis models28 
 Enterococcal proteases-The  gelatinase (GelE), serine 
protease(SprE) of E.faecalis mediate virulence by several 
mechanisms like  degradation of host tissues and  modification 
of immune components. 
 Coccolysin, an extracellular metalloendopeptidase secereted by 
E.faealis strains mediate virulence by inactivating the vasoactive 
peptide –endothelin. 
 Extracellular superoxide, secereted in large amounts by most of 
E.faecalis,E.faecium strains enhance virulence in mixed flora 
abcesses.  
Enterococcal surface proteins: 
 Aggregation substance –a plasmid-encoded surface protein 
which promotes enterococcal adherence to epithelial cells and 
clumping of organisms facilitating plasmid exchange . It also 
favors growth of cardiac vegetations in rabbit endocarditis 
model28,45. 
 The surface proteins – Ace(adhesion of collagen of E.faecalis) 
and Acm(homologue adhesion of E.faecium) are Microbial 
surface components recognizing adhesive matrix molecules 
(MSCRAMM)  mediate bacterial attachment to host proteins like 
collagen,fibrinogen , fibronectin. 
 Other surface proteins similar to MSCRAMM playing role in 
virulence by mediating bacterial attachment are second collagen 
adhesion of E.faecium(Scm),enterococcal surface protein (Espfc) 
of E.faecalis and of E.faecium(Espfm), surface proteins (Fms) of 
E.faecium,SgrA( which binds to basal lamina 
components).EcbA(binds to collagen type V)(har,Murra). 
 Lipoteichoic acid  (group D antigen) functions in modulating 
immune response by inducing the production of TNF and 
Interferons(kony). 
 Pili is  present  in both E.faecalis and  E.faecium which mediates 
attachment and invasion into host tissues and are targets of 
immunotherapy. 
 Bio-films produced by enterococci alter the efficacy of anti-
enterococcl agents and play a role in pathogenesis of 
experimental endocarditis and UTI11,44. 
 Polysaccharides ( on bacterial cell surface)  contribute to 
pathogenicity by interfering with phagocytosis. E.faecalis 
possesses three distinct classes of capsular polysaccharides 
which are potential targets of immunotherapy.7 
 
Other virulence factors: 
 E.faecalis stress protein Gls24 – responsible for enterococcal 
resistance to bile salts important in pathogenicity of endocarditis . 
 hyl Efm- containing plamids found in  E.faecium , increase the 
colonizing capacity. 
CLINICAL SYNDROMES:6,7 
Urinary tract infections: 
Nosocomial UTI is the most common infection caused by the 
Enterococci , associated with anatomic abnormalities of genitourinary 
tract, instrumentation, indwelling catheters, prior antibiotic use and 
recurrent UTIs. It is the third most common agent isolated from catheter-
associated UTIs in the United States with E.faecium being the 
predominant species(40%) followed by E.faecalis (25%) and other 
species(35%)6.In the hospital setting differentiating infection from 
colonization may be difficult and the factors like presence of leucocytes 
in urine along with systemic manifestations(fever), local symptoms and 
signs , and a colony count of > 105 CFU/ml may help in this regard.6,7. 
Removal of catheter itself may be enough to eradicate this agent. The 
complications associated with Enterococcal UTI are pyelnephritis, 
perinephric abcess and recurrent bacteremias6,7. 
Bacteremia and Endocarditis:  
Bacteremia without endocarditis is the most common presentation 
of these two with Enterococci being the leading cause of nosocomial 
bacteremias. Intravascular catheters and other devices are  the 
commonest sources and others like genitourinary  and biliary tracts, 
pelvic and intra abdominal foci, UTIs, wound and bone infections also 
contribute. E.faecium bloodstream infections carry the worse prognosis 
because of higher prevalence of  ampicillin and vancomycin resistance 
and fewer therapeutic options. The association between Enterococcal 
bacteremia, meningitis and Strongyloides hyperinfection syndrome in 
immunocompromised individuals is well known7,11. 
Enterococci are important causative agents of both community 
acquired and hospital associated endocarditis especially in elderly, 
debilitated patients with comorbid conditions6. It can affect both native 
and prosthetic valves, mitral and aortic valves affected commonly. 
E.faecalis is isolated more frequently than E.faecium and other species. 
Malignant and inflammatory conditions and procedures involving genito 
urinary or gartrointestinal tracts  serve as the source of origin. Typical 
presentation involves a subacute course with fever, malaise, weight loss ,  
cardiac murmur and lessfrequent peripheral signs. Heart failure is the 
common complication followed by embolic phenomina,the most 
common end organ being brain. Mortality is mainly due to heart failure 
or embolization and the overall mortality rate ranges  from 11% to 35%6. 
Meningitis: 
Enterococci are   uncommon agents of meningitis accounting for 
only 4% of all  meningitis cases and presents as two forms- Spontaneous 
and post operative meningitis. The most common species isolated is 
E.faecalis followed by  E.faecium , E.gallinarum and other species. 
Spontaneous meningitis is a community acquired in patients with many 
comorbid conditions like Diabetes, renal failure, malignancy, 
immunosuppression and in children with CNS pathology. Post operative 
meningitis is hospital acquired  in the presence of shunt devices. Both  
forms have similar clinical features – acute course with fever, altered 
mental status and signs of meningial irritation. Complications include 
hydrocephalus, brain abcess and stroke with overall mortality of 20%6,7.      
Intraabdominal,pelvic and soft tissue infections:                
Enterococci produce spontaneous peritonitis in cirrhotic patients 
and patients on chronic ambulatory peritoneal dialysis. It is usually 
isolated along with gram negatives and anaerobes and its presence 
indicates  treatment failure and  increases the postoperative  
complications, and mortality. The emergence and spread of VRE and 
multi-drug resistant E.faecium isolates worsens the situation further. 
Enterococci  rank  third as the causative agents of hospital 
acquired surgical-site infections6,12. E.faecalis is the common species 
isolated Enterococci often colonize the decubitus ulcer and diabetic foot 
and can be a source of bone infections. 
Other infections: 
It also causes neonanatal infections like late onset sepsis , 
bacteremia, pneumonia  and UTI in the presence risk factors like 
prematurity, low birth weight and indwelling devices. It also causes 
bone and joint infections. 
LABORATORY  DIAGNOSIS: 
Collection, transport and storage of specimens: 
The specimens usually submitted are blood, urine, wound 
exudates and secretions from other sites/ swab specimens and standard 
method of collection of these samples is adequate 45.  
As Enterococci are nonfastidious organisms, relatively resistant to 
adverse environmental conditions, no special methods of transport and 
storage of clinical specimens is needed. Specimens can be transported to 
the laboratory using any of the transport medium or on swabs that are 
kept dry 44. 
Enrerococci grown on agar slants of Brain heart infusion 
agar/Tryptic soy agar can be stored for several months at 4ºC. The 
preferable methods would be storage as frozen cultures at - 70ºC of 
heavy cell suspensions made  in defibrinated sheep or rabbit blood or in 
10% skimmed milk solution containing 10% glycerol.  They can also be 
stored in cryo preservative media at -20ºC for many years. Lyophilized 
cultures can be stored indefinitely44. 
Direct examination: 
The direct microscopic examination of gram stained smears of 
normally sterile clinical specimens like blood is useful in diagnosing 
Enterococcal infections. However, only a presumptive report of 
“ presence of Gram positive cocci” can be given in case of non sterile 
specimens. Direct detection of Enterococci especially VRE from clinical 
specimens and surveillance specimens  (feces,rectal swab) by using  
conventional and real-time PCR based methods have   been developed 
and  evaluated . A multiplex real-time PCR assay (Light cycler septifast 
test) for rapid detection and identification of major pathogens of 
nosocomial  bacteremia in whole blood  is available for use in the United 
States. 
Isolation procedures: 
Clinical specimens from normally sterile body sites, can be plated 
onto tryptic soy agar, brain heart infusion agar or blood agar base 
containing  either 5%sheep,horse or rabbit blood for primary isolation of 
Enterococci . Samples for blood culture are inoculated into conventional 
blood culture systems. Most of the clinically relevant species grow well 
at 35 to 37ºC. For  specimens obtained from non sterile sites  especially 
when contaminated with gram negative bacilli, selective media 
containing sodium azide, bile salts, antibiotics and esculin , tetrazolium  
can be used for primary isolation. However  not all Enterococci grow on 
selective media. Use of enrichment  broth(Enterococcosel broth- BEA 
medium with 6µg vancomycin)   increases the recovery rate of 
Enterococci especially VRE from feces and rectal samples especially 
surveillance specimens. Various chromogenic media from different 
manufacturers also have been evaluated for the primary isolation.     
Identification of Enterococcus species:    
The genus identification of a catalase negative, Gram positive 
coccus as  “ Enterococcus”  is based on the above said tests in genus 
description. Enterococal  species  can be classified into five 
physiological groups  of  species as proposed by Facklam and Collins, 
based  on acid production  from mannitol and  sorbose and hydrolysis of 
arginine45  . Further speciation is based on acid production from sugars 
like arabinose, sorbitol, raffinose, sucrose, pyruvate, trehalose   and 
reduction of 0.04% tellurite, motility and pigment production. 
 Group I – consists of 9 species. They  produce acid from 
mannitol and sorbose, arginine is not hydrolysed. E.avium, 
E.raffinosus are the clinically relevant species in this 
group.Others are E.gilvus, E.pallens, E.saccharolyticus, 
E.malodoratus,E.pseudoavium, E.divriesei  and 
E.hawaiiensis. 
 Group II – consists of 8species. They  produce acid from 
mannitol only and not from sorbose andarginine is 
hydrolysed. Majority of the isolates recovered from human 
sources likeE.faecalis ,E..faecium, E.gallinarum, 
E.casseliflavus  belong to this group. Others  are E.mundtii, 
E.haemoperoxidus, E.sanguinicola, E.ythailandicus. 
 Group III –consists of 6 species. They don’t produce acid 
from mannitol and sorbose, but hydrolyse  arginine. It 
includes E.dispar, E.canintestini, E.hirae, E.durans, E.ratti, 
and  E.villorum. 
 Group IV – includes 8 species. They don’t produce acid 
from both mannitol and sorbose and  arginine is not 
hydrolysed. It includes E.caccae, E.cecorum, 
E.aquimarinus, Ephoeniculicola, E.sulfureus, E.asini,  
E.silesiacus, E.termitis. 
 Group V – consists of 6 species. They ferment only 
mannitol producing acid but not sorbose and arginine also 
not hydrolysed. E.canis, E.columbae, E.moraviensis, 
E.camelliae,E.hermanniensis, and  E.italicus are the species 
included in this  group. 
Various commercial identification systems – manual, semi-
automated and  automated  systems like API 20S, API Rapid ID32 
STREP, Crystal gram positive ID system, Gram positive identification 
card of Vitek  system etc..are available. These are reliable for the 
detection of most common species E.faecalis and to a lesser extent 
E.faecium. 
 Molecular methods45 like SDS polyacrylamide gel 
electrophoresis analysis  of whole cell proteins (WCP) profile and 16S 
rRNA gene sequencing are extensively evaluated for identification of 
different Enterococcal species. The  16S rRNA gene (1500 base span) 
sequencing  is the most frequently used molecular method for 
identification of Enteococcus species. However it should be used along 
with phenotypic characterization for diagnostic purposes. PCR based 
techniques use amplification of ddl or sodA genes for accurate and rapid  
identification are also available. DNA probe kit Accuprobe(Gen-
Probe,Inc) directly detects Enterococci in blood. FISH (Fluorescent In 
Situ Hybridization) techniques (PNA FISH) been evaluated for 
identification of Enterococci from positive blood cultures. 
Analysis of chromosomal restriction profiles by pulsed field gel 
electrophoresis (PFGE) has been extensively evaluated for strain typing 
and epidemiological outbreaks  allowing the identification of 
predominant clonal complexes and resistance genes  - HLAR high level 
aminoglycosides resistance and VRE- vancomycin resistance.   Among 
the recent methods like MLST- Multilocus sequence typing and MLVA- 
multi locus variable number tandem repeat analysis , MLVA  is less 
expensive and rapid  compared to MLST.  
 
ANTIMICROBIAL SUSCEPTIBILITY AND RESISTANCE 
MECHANISMS:6,7,8,11,35,45 
Enterococci exhibit both intrinsic and acquired resistance to 
several of the commonly used antibiotics. Intrinsic resistance is 
chromosomally mediated and is found in all or most of Enterococci  and 
is against -lactams (cephalosporins, penicillinase resistant penicillins), 
lower concentration of aminoglycosides, fluoroquinolones,  
trimethoprim-sulfmetoxazole  and  clindamycin. However the most 
recommended regimen of combination of  a cell wall active agent (-
lactams)  and an aminoglycoside, for serious infections like endocarditis 
and in  immunocompromised patients, overcomes the intrinsic resistance 
by exerting synergistic bactericidal killing. This is achieved by the 
facilitation of aminoglycoside entry into the bacteria by the damage 
caused by the cell wall active agent.   
Acquired resistance is variable and results from either mutations 
in existing DNA or acquisition of new genetic determinants carried on 
plasmids / transposans.  It rather confers  resistance to several classes of 
antibiotic agents including chloramphenicol, tetracyclines, MLS- 
macrolides-lincosamide-streptogramins, higher concenrtrations of 
aminoglycosides and -lactams, glycopeptides, rifampin  and 
nitrofurantoin than to a single agent. Recent reports highlight the 
emergence of resistance to the newer agents like linezolid, daptomycin 
and quinupristin-dalfopristin7. 
-LACTAM  RESISTNCE: 
High level resistance to penicillin and ampicillin, as a result of  
low affinity penicillin binding proteins (especially PBP5- amount 
produced proportionate to resistance) is  a common occurrence among 
enterococci. - lactamase production in Enterococci is  a rarely 
identified one and is constitutively expressed and is of low level 
resistance, whereas in other bacteria it is an inducible resistance11 . 
Enterococci susceptible to penicillin are predictably susceptible to 
ampicillin  and other -lactams. But ampicillin susceptibility doesn’ t 
predict susceptibility to penicillin , separate testing with penicillin is 
required. Ampicillin susceptibility can be used to predict imipenem 
susceptibility in case of E.faecalis species. Nitrocefin based test  is 
needed for the reliable detection of -lactamase production in 
Enterococci, as disc diffusion and dilution methods are not reliable. 
RESISTANCE TO AMINOGLYCOSIDES (HLAR- High Level 
Aminoglycoside  Resistance ): 
 Aminoglycoside  resistance in Enterococci  is  due to  two  types 
of mechanisms;  
a) Low  permeability to  aminoglycosides leading to 
moderate level resistance (MIC 62-500µg/ml), which 
can be overcome by synergism with cell wall active 
agents 
b)  Production of  inactivating enzymes (acetyl 
transferase,adenyl transferase)  or ribosomally 
mediated  resistance which is of high level (MIC  
2,000µg /ml).  
Gentamicin resistance is primarily due to the presence of 
inactivating enzyme 2” -phosphotransferase-6’ -acetyltransferase, 
resulting in resistance to gentamicin  tobramycin , amikacin and other 
aminoglycosides except streptomycin. The enzyme adenyl transferase 
operates in streptomycin resistance strains, but these strains are 
susceptible to gentamicin. Hence gentamicin and streptomycin – both 
should  be tested individually to predict  the resistance to 
aminoglycosides. 
Resistance to either aminoglycoside or cell wall active agent ( -
lactams, glycopeptides) results in resistance to the synergistic killing of 
Enterococci by the combination therapy and constitute a critical 
therapeutic problem. Hence detection of resistance to these agents is 
critical for the prediction of synergy of the combination therapy. 
Screening of the clinical Enterococcal isolates to detect high level 
aminoglycoside resistance( HLAR) can be done   by either disc diffusion 
using high level gentamicin(120µg)(HLG) and high  level 
streptomycin(300µg)(HLS)  discs or single concentration agar dilution 
method gentamicin  500µg/ml, streptomycin 2000µg/ml)  are 
available. Resistance to streptomycin is due to altered ribosomal target 
and modifying enzymes, whereas resistance to gentamicin is due to 
modifying enzymes  encoded by altered genes. Gentamycin  resistance 
predicts resistance to other aminoglycosides except streptomycin where 
as streptomycin resistance indicates resistance to streptomycin only. 
Emergence of Vancomycin resistance in Enterococci  worldwide  
poses serious problems in  managing these patients as only very few 
options  remain there for treatment. Vancomycin resistance is highly 
prevalent in E.faecium than in E,faecalis, the detailed discussion of 
which  is presented  in the  following pages.  
TREATMENT : 
The suggested therapeutic options for the treatment of  serious 
Enterococcal infections like endocarditis, bacteremia is combination 
therapy with a cell wall active agent (-lactams,glycopeptides) and an 
aminoglycoside. Among the -lactams, aminopenicillins (ampicillin, 
amoxicillin)  and ureidopenicillins (piperacillin) are the most active ones 
followed by penicillinG and imipenem. The only two aminoglycosides 
recommended for synergistic therapy are gentamicin and streptomycin. 
Aminoglycoside  monotherapy is  not effective. Vancomycin  is an 
alternative to -lactams  for E.faecalis infections but less useful in 
E.faecium because of the common occurrence of  vancomycin resistance  
in these strains. Cephalosporins are inactive against enterococci  except  
ceftobiprole  for E.faecalis  infections . For the treatment of   urinary 
tract infections single agent like nitrofurantoin, fosfomycin ,ampicillin 
or amoxicillin can be used. 
Linezolide and Quinupristin/Dalfopristin are FDA approved drugs 
used in some VRE infections, both are bacteriostatic drugs and used as 
an alternative to the standard drugs .  
VANCOMYCIN   RESISTANT   ENTEROCOCCI  (VRE) 
Epidemiology: 
The first report of  isolation of vancomycin resistant E.faecalis 
and E.faecium came from England in 1988 by  Uttley et al44 and 
thereafter from France also11. Now the emergence  of  vancomycin 
resistant Enterococci are being reported worldwide from many countries  
- European countries – Greece , Portugal , United kingdom and United 
States and also from Asia7,11. The presence  of  VRE was associated  
with the use of avoparcin- a glycopeptide used as a growth promoter  in 
animal feeds and was banned from European  countries. The rates of 
VRE is lower in Scandinavian countries and Netherlands  due to strict 
adherence to infection control practices and   in Latin America   VRE  
rates ~ 4% 7.  Higher rates of VRE isolation  in United States and Asia 
could be attributed to higher usage  of human  antibiotics in these 
countries. 
VRE now accounts for about 30%  of  all Enterococcal infections, 
the most common agent being E.faecium  (>90%)  ( mand).  Previous 
studies have reported that patients with VRE bacteremia were about 2.5 
times more likely to die than those with VSE bacteremia indicating  
vancomycin resistance-a poor  prognostic sign in critically ill patients6. 
The increased  nosocomial VRE  infection  rates  were mainly due to the 
increased VRE  infections in ICUs( intensive care units) , however now 
the trend is also being observed in  nonICU  patients.  VRE outbreaks  in 
hospitals could be attributed to spread from  patients colonized with 
VRE , however VRE have been isolated from  hospital environment  
during outbreaks11,45. 
Previous studies11, conducted to assess community acquired VRE 
state that there is little evidence for significant transmission  of  VRE to 
healthy adults in the community. However   the possibility of  
transmission to community members from patients colonized  with VRE 
could not be denied when the colonized patients leave the hospital 11. 
In India , vancomycin  resistance  among the  Enterococci  is  
emerging slowly.  Previous studies have reported  vancomycin 
resistance in Enterococci   ranging from 0-5.6% 2,22.  They   also  
reported   emergence of  both Van A and Van B types,  raising  concern  
about  the  serious  nature  of  the problem . 
VANCOMYCIN   RESISTANCE  AMONG  ENTEROCOCCI:  
Vancomycin is one of the two glycopeptides currently in use  to 
treat  Enterococcal infections,  the  other  one  being  teicoplanin.  The  
mechanism  of  action  of  these  drugs  is inhibition of  
transglycolysation  and  transpeptidation of  the pentapeptide units – the 
last step in peptidoglycan synthesis  thereby interfering with the cell wall 
synthesis in bacteria6. 
VRE strains are classified based on phenotypic and genotypic 
characteristics as seven types of glycopeptides resistance – Van A , Van 
B, VanC, VanD , VanE, VanG and VanL 45. Some  of them have 
subtypes also. The clinically relevant phenotypes are  VanA and VanB 
and are usually associated with E.faecalis and E.faecium and Van C  is 
intrinsic toE.gallinarum, E.casseliflavus.. The genotype describes the 
gene clusters encoding  the  enzymes involved in the generation of 
structural components. These  are  the  different  peptidoglycan  
precursors  that  have decreased binding affinity for vancomycin , 
teicoplanin or both.  These altered structural components result in 
phenotypic resistance.  
The glycopeptide- susceptible strains have, in their cell wall ,  “ D-
alanyl-D-alanine”  depsipeptide as the terminal end of peptidoglycan side 
chains. The antibiotic  binds to this depsipeptide  and  there  by inhibit 
the cell wall synthesis.  In glycopeptide – resistant  strains, this 
depsipeptide is replaced  with “  D-alanyl-D-lactate”   or  “ D-alanyl-D-
serine” . These glycopeptide resistance types are described as follows, 
 VanA  – it is encoded by Van A gene and is an inducible high level 
resistance to both vancomycin (MIC 64-1,000 µg/ml) and teicoplanin ( 
MIC 16-512µg/ml).  It  is  mediated  the transposon  Tn1546 .The 
altered gene product is  “ D-alanine-D-lactate”  . it is distributed in the 
following species E.faecalis,E.faecium, E.avium, E.casseliflavus, 
E.durans, E.gallinarum, E.mundtii, E.raffinosus and E.sanguinicola. 
VanB – is an acquired inducible, variable level  resistance to 
vancomycin (MIC 8-1,000µg/ml), but susceptible to teicoplanin (MIC 
0.5-1µg/ml). The  gene is located in plasmid   and mediated by  
trasposons Tn1547,Tn1549,Tn5382. The gene product is “ D-alanine-D-
lactate” . Ithas 3 subtypes (Van B1-B3) and  is distributed in 
E.faecalis,E.faecium, E.durans and E.gallinarum. 
Van C- encoded by constitutively expressed VanC gene located in 
chromosome and exhibits intrinsic low level resistance to vancomycin 
(MIC 2-32µg/ml) and susceptible to teicoplanin (MIC 0.5-1µg/ml). the 
end product is  “ D-alanine-D-serine”  and  has 4 subtypes distributed in 
E.gallinarum  (C1) and   E.casseliflavus (C2-C4). 
Van D – encoded by Van D gene, constitutively expressed , 
chromosome mediated,  moderate level resistance  to vancomycin (MIC 
64-128µg /ml) and susceptible / resistant to teicoplanin (MIC 4-64µg 
/ml) . The product is  “ D-alanine-D-lactate”  and  is found in  E.faecalis, 
E.faecium,  E.avium and E.gallinarum. 
Van E, VanG  and VanL – encoded by Van E,VanG , VanL genes 
located in chromosome, results in inducible  intermediate level 
resistance  to vancomycin  (MIC 8-32µg/ml) , susceptible to teicoplanin 
(MIC 0.5-1µg/ml). The end product is  “ D-alanine-D-serine”  and is 
found in E.faecalis.The identification of the different genotypes is 
crucial for therapeutic and infection control purposes.             
RISK   FACTORS   associated  with  VRE 6,7,11,36,45: 
As  the  earlier  reports  of  VRE  were  from  ICUs, the  risk  
factors associated with  colonization  and  infection with VRE   have 
been analyzed.   The various risk factors are as follows:  
• Presence  of  immunosuppression( haematologic 
malignancy,/bone marrow transplantation) 
•  Presence of Co-morbid   conditions like diabetes, renal failure, 
high APACHE ( Acute physiology  and Chronic Health 
Evaluation) score, malignancy, 
• Longer duration of  hospital stay 
• Intrahospital transfer to another ward 
• Residence in a long term care facility 
• Contact with another colonized /infected patient 
• Invasive procedures 
• Previous exposure to broadspectrum antibiotics – 
cephalosporins, vancomycin. 
• Use of enteral tube feeding/ sucralfate 
• Exposure to contaminated medical equipment 
• The most important being exposure to heath care personnel  
nursing to a known VRE patient. 
Colonization and Infection: 
The first step in  the  infective process  appears to be the 
colonization  of  the gastro intestinal tract.  In most instances ,VRE 
isolation is from colonized patients  than infected individuals. For every 
one infected patient there could be as many as 10 
colonizers11.colonization usually involves gastrointestinal tract, perineal 
skin and rarely oral cavity and other sites.11  
VRE  infections usually occur in critically ill and debilitated  
hospitalized patients. The  sites usually involved  in  VRE infections are 
bloodstream, intravascular catheters, surgical wounds, prosthetic 
devices, intra-abdominal sites and urinary tract. Various  authors have 
reported  mortality ranging from 46%-70%  among patients infected 
with VRE11. The  mortality is higher in patients with prolonged VRE 
bacteremia  such as  neutropenic patients , liver transplant recipients and  
seriously ill patients with co-morbid conditions like chronic renal 
failure. It is difficult to differentiate between colonization and infection, 
as mostly these infections are polymicrobial  in nature and are recovered 
along with many known pathogens45.   
Source of infection and transmission of VRE: 
The source of infection could be Endogenous – patients own 
Gastrointestinal tract in previously colonized individuals or Exogenous  
as contaminated environmental surfaces and ,medical devices –bed rails, 
linen,doorknobs,bed pans,stethoscope and blood pressure cuffs6,11. VRE 
are resistant to dessication and extreme temperatures and hence persists 
for days to months . Contaminated food products  may  be a reservoir in  
non hospitalized  individuals11.   
The most common mode of transmission is through the 
contaminated  hands of healthcare workers in nosocomial VRE 
infections11 and  less commonly contact with contaminated equipments 
(clinical thermometers), and contaminated surfaces. 
Laboratory Detection of  VRE: 
  Identification to  species level, especially motility and pigment 
production differentiates the Van C phenotype (i.e) intrinsically   
resistant E.gallinarum and E.casseliflavus  from others. 
  Presumptive identification of  VRE   is done by vancomycin 
screen agars containing  6-8µg of vancomycin per ml of media. 
 Confirmation is by determination of minimum inhibitory 
concentration of  vancomycin and teicoplanin for the suspected 
VRE isolates.  
 The genotypic expression can  be detected by molecular methods 
– polymerase chain reaction  for the amplification of  
vancomycin resistance genes- Van A, Van B and Van C, either 
conventional or multiplex PCR or by DNA hybridization probes. 
Treatment of VRE infections: 
The suggested therapeutic options for serious VRE infections are 
• Combination therapy with high dose of  cell wall active agents( 
ampicillin) and an aminoglycoside( if there is no acquired  
resistance observed for either of the agents ) 
• Linezolid – It is an FDA approved drug for treatment of VRE 
infections caused by both E.faecalis, E.faecium .  It belongs to 
oxazolindones and it is a bacteriostatic drug. However  it is 
recommended only as an  alternative to other agents , but may 
play a crucial role in the treatment of meningitis and other CNS  
infections. 
• Quinopristin-Dalfopristin – it is FDA approved,  parentral 
semisynthetic streptogramin type A and B. it is also a 
bacteriostatic. It is active against E.faecium only and not active in 
E.faecalis  
• Daptomycin- it is a lipopeptide active against both E.faecalis and  
E.faecium but it is not FDA approved. It is used as an alternative 
in situations of therapeutic failure of  the commonly used agents. 
• Other antimicrobials- Quinolones(ciprofloxacin and 
moxifloxacin), tetracyclines(doxycycline and minocycline), 
chloramphenicol can be used in combination  therapy along  with 
other agents. 
PREVENTION AND CONTROL MEASURES4: 
CDC’ s Hospital Infection control practices advisory committee has 
established certain guidelines and recommendations for prevention of 
VRE spread. 
• Prudent use of vancomycin- inappropriate use of vancomycin is a 
risk factor for VRE colonization and infection and also emergence 
of vancomycin resistant Staphylococci. The medical staff should 
be educated about the appropriate or acceptable use of 
vancomycin(MRSA treatment, Severe antibiotic associated colitis 
as a second line agent , major surgical procedures involving 
implantation of prosthetic devices) 
• Education of   the personnel -special awareness should be created 
among all health care workers and patient care givers about the 
epidemiology and impact of VRE infections. 
• Implementation of surveillance procedures ( feces cultures) for 
early detection of VRE colonization . 
• Infection control procedures aiming to limit cross contamination- 
isolation of known VRE patients and colonizers, strict adherence 
to hand washing. 
 
MATERIALS AND METHODS: 
Study  Design : Cross sectional study 
The present study was conducted in Department of  Microbiology in 
Government Stanley Medical College and Hospital, Chennai, India.     
Study Population: 
          Patients attending outpatient  department and  inpatients of Govt. 
Stanley Medical College and Hospital, Chennai. 
Study Period:   
July 2011 to November 2012- one year and 4 months 
Materials : 
          A total of   about21,045 clinical specimens such as urine, blood, 
pus, tissue fluids and feces obtained from all age groups of patients 
submitted to the microbiology laboratory , were analyzed and a total of  
240  Enterococcal isolates  recovered from these clinical samples were 
taken for further study.  
The study was approved by our Institutional Ethical Committee . 
 
METHODOLOGY: 
Collection  and Processing of samples: 
The various specimens such as urine, blood, wound  exudates , 
pus and feces submitted to the microbiology  laboratory   from both 
inpatients and outpatients for bacteriological analysis were  included in 
this study. The Enterococcal isolates grown from the above said samples 
were taken for further study and  identified by standard techniques as 
follow.6,7,8,28,45 
IDENTIFICATION OF THE  GENUS: 
The suspected Enterococcal isolates grown on the primary plating 
media such as blood agar and Mac Conkey agar were selected for further 
identification.  
Preliminary tests  for identification  such as Gram stain, catalase 
test and motility test  were performed  on the selected isolates. Catalase 
negative, Gram  Positive cocci in pairs and short chains were selected 
and processed further. For all the tests ATCCEnterococcus faecalis 
29212 is included as a control strain. 
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Bile esculin agar: 
The suspected isolates were then inoculated onto Bile esculin  
agar ( containing 40% bile) ,  incubated aerobically  at 37ºC overnight. 
The next day the isolates showing black discoloration of the medium due 
to hydrolysis of  esculin to esculetin  were identified as BEA positive. 
After studying the colony morphology of each isolate plated on blood 
agar , MacConkey agar and  bile esculin agar , the isolates which were  
nonhemolytic  on  blood agar,  showing magenta pink colored tiny 
colonies on MacConkey agar  and  BEA positive  were selected for 
further biochemical reactions. 
Heat tolerance test11,38: 
The suspected Enterococcal isolates along with the control strains 
were tested for heat tolerance11,38  by inoculating them into BHI  broth 
and  incubating them along  at 60ºC for 30 minutes in a water bath. 
Subcultures from the broth were done on blood agar and MacConkey 
agar  before incubation and  at intervals of 10 min, 20min  and 30 
minutes after incubation .  ATCC E.faecalis  29212  was used as  a 
positive control. 
The growth of the positive control was checked before reading 
other isolates. The ATCC control strain has shows growth both before  
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and after heating the broth  at 60ºC for 30 minutes.   The isolates  
showing  growth before and   after 30min of  incubation at 60ºC   were   
taken as heat tolerant Enterococcal isolates .   
Salt tolerance: 
Salt tolerant  property of the suspected Enterococcal isolates were 
tested by inoculating 2 to 3  identical colonies of  suspected  isolates  
along  with  control strains  into a tube  containing  nutrient broth with 
6.5% sodium chloride and incubated at 37ºC for 24-72 hours. 1% 
bromocresol purple is added as an indicator to detect yellow 
discoloration on growth. The  broth  showing  turbidity with or without 
yellow discoloration is taken as positive reaction and is confirmed by 
subculturing the  broth  on blood agar / MacConkey agar. The salt 
tolerant isolates grow well even in the presence of 6.5% NaCl.  
Salt  tolerant , BEA positive isolates, which were able to grow on 
MacConkey agar and at   temperatures of > 45ºC  were  identified as  
Enterococci and selected for further speciation. 
Speciation of the Enterococcal isolates was done based on the 
Faklam and Collins conventional  identification scheme20. Enterococci 
were classified into the physiological  groups  I-V based primarily  on 
arginine dihydrolysis, fermentation of mannitol and sorbose . Further 
speciation was based on acid production from specific carbohydrates and 
motility and pigment production. 
Arginine dihydrolysis:   
Arginine dihydrolysis was tested by inoculating the isolate  into a 
tube of  Moeller’ s decarboxylase broth containing arginine  and a control 
tube ( without arginine),  overlaid  with  sterile liquid paraffin and 
incubated  for seven days at 37ºC .  Control  strains were also included 
in the test. Development of deep purple colour due  to  alkalinization 
after an initial change to yellow colour read as positive reaction. 
Persistant yellow color indicates negative reaction. 
Mannitol motility medium: 
The motility and fermentation of  mannitol was tested by stab 
inoculating  the  isolates ( including positive and negative control)   into 
the medium and   incubated at 37ºC overnight to detect the motility and 
acid production from mannitol. 
To test the  utilization of carbohydrates,  the Enterococcal isolates  
were inoculated into carbohydrate fermentation medium containing 1% 
each of pyruvate, arabinose, sorbitol, sucrose, sorbose and raffinose  and  
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incubated at 37ºC overnight to detect acid production indicated  by 
colour change to yellow. 
Pigment production is tested by growing the isolate in blood agar 
and sweeping few colonies using a cotton tipped swab. Pigment 
production is indicated by yellow/orange tinge on the swab.28 
The additional tests performed were  production of black coloured   
colonies on 0.04%  tellurite agar ,  which is a feature of E.faecalis. 
Enterococcus faecalis – characteristics: 
Gram stain – gram positive cocci in pairs and short chains. 
Catalase – Negative 
Motility – Nonmotile 
Colony morphology : 
Blood agar ( 5% sheep blood agar) :     – or non hemolytic,  
small,   cream colored,smooth colonies with entire edge. - hemolysis is 
observed  when  human, horse or  rabbit blood is used. 
MacConkey agar : lactose fermenting, magenta  coloured colonies.    
Bile esculin  agar – cases blackening of the medium- hydrolyses esculin 
in the presence of 40% bile. 
Heat tolerance :   survives  a temperature  of 60ºc for 30 minutes. 
Salt tolerance :    survive a  salt concentration of 6.5% NaCl  
Mannitol motility medium :   nonmotile , ferments mannitol by 
producing acid. 
Pigment production :  pigment not produced. 
Arginine dihydrolysis  :  hydrolyses  arginine – produces deep purple 
colouration after initial colour change to yellow. 
0.04% tellurite agar :  produces black coloured colonies . 
Carbohydrate utilization (1%) :  ferments pyruvate and sorbitol, but  not 
arabinose , sorbose. 
Enterococcus faecium -  characteristics: 
Gram stain – gram positive cocci in pairs and short chains. 
Catalase – Negative 
Motility – Nonmotile 
Colony morphology : 
• Blood agar( 5% sheep blood agar) :     – or non hemolytic,  
small,   cream colored,smooth colonies with entire edge. - 
hemolysis is observed  when  human, horse or  rabbit blood is 
used. 
• MacConkey agar : lactose fermenting, majenta  coloured colonies.    
• Bile esculin  agar – cases blackening of the medium- hydrolyses 
esculin in the presence of 40% bile. 
Heat tolerance :   survives  a temperature  of 60ºc for 30 minutes. 
Salt tolerance :    survives salt concentration of 6.5% NaCl. 
Mannitol motility medium :  nonmotile , ferments mannitol by 
producing acid. 
Pigment production :  pigment not produced. 
Arginine dihydrolysis  : hydrolyses  arginine .                                  
Carbohydrate utilization :   ferments arabinose, sorbose –not fermented. 
Others :  Inherently resistant to Imipenem . 
Other species  of Enterococci  were differentiated  based on the 
following characteristics8, 20,2845 
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Enterococcal 
species 
Arginine 
dihydrolysis 
Mannitol 
Motility 
medium 
Fermentation 
of sugars 
Motility & 
Pigment 
production 
E.raffinosus 
Group I 
Not 
hydrolysed 
Fermented 
Nonmotile 
Raffinose, 
Arabinose 
Sorbose 
fermented. 
Nonmotile   
no pigment 
E.sulfurous 
GroupIV 
Not 
hydrolysed 
Not 
fermented 
nonmotile 
Raffinose 
,arabinose 
fermented. 
Sorbose not 
fermented 
Yellowish 
pigment 
produced. 
E.columbae 
Group V 
Not 
hydrolysed 
Fermented 
nonmotile 
Raffinose  
Arabinose 
fermented sorbose 
not fermented 
No 
pigment 
E.durans 
Group III hydrolysed 
Not 
fermented 
Nonmotile 
Raffinose ,sucrose 
&, pyruvate not 
fermented. 
 
 
E.hirae 
GroupIII hydrolysed 
Not 
fermented 
nonmotile 
Raffinose&sucrose 
fermented. 
Pyruvate not 
fermented 
 
E.dispar 
Group III Hydrolysed 
Not 
fermented 
Nonmotile 
Raffinose sucrose 
&pyruvate 
fermented. 
 
E.avium 
Group I 
Not 
hydrolysed 
Fermented 
nonmotile 
Arabinose,sorbose 
fermented, 
raffinose  not 
fermented 
 
E.mundtii 
Group II hydrolysed 
Fermented 
nonmotile 
Arabinose 
fermented 
Yellow 
pigment 
produced 
 
 
 
 
ANTIBIOTIC SUSCEPTIBILITY TESTING : 
Antibiotic susceptibility testing of all the Enterococcal isolates 
and the screening and confirmatory tests for the detection of specific 
resistance mechanisms like Penicillin resistance , HLAR and 
Glycopeptide resistance were performed as per  CLSI Standards13,14. 
ANTIBIOGRAM  BY  KIRBY-BAUER DISC DIFFUSION 
METHOD13 : 
The antibiotic susceptibility pattern of the isolates was determined 
by  on Mueller –Hinton agar (MHA) .The bacterial inoculums is 
prepared by inoculating few identical colonies in a nutrient broth and 
incubated for 3-6hrs. It is standardized with 0.5 McFarland turbidity 
standard ( 1.5×108 CFU/ml) before  inoculation , if the bacterial 
suspension is too thick it should be dilute to match the standard and if it 
is lees tubid ,it has to incubated further. 
  After standardization ,a sterile swabis dipped in that broth and the 
excess fluid is squeezed out by pressing on the side of the test tube, and 
it is streaked on the surface of the agar three times, turning the plate at 
60º  each time to produce a lawn culture of the organism.Then it is 
allowed to dry and the antibiotic discs are placed over the lawn culture 
within 15 minutes of inoculation.  
The antibiotics tested were as follows – for urinary isolates 
penicillin 10 U, ciprofloxacin 5µg, doxycycline 30µg, high level 
gentamicin 120µg , high level streptomycin 300µg, vancomycin 30µg 
and teicoplanin 30µg . For  isolates from other sites  like pus, wound, 
blood –penicillin 10/ ampicillin 10µg,erythromycin 15µg, 
chloramphenicol 30µg, doxycycline 30µg, high level gentamicin 120µg , 
high level streptomycin 300µg, vancomycin 30µg and teicoplanin 30µg. 
All the materials and antibiotic disc were procured from Himedia 
laboratories Pvt.Ltd. Mumbai. The inoculated plates were incubated 
aerobically at 37ºC overnight.     Next day the zone of inhibition of the 
bacterial growth  around each disc  is measured using ruler  under 
reflected light except for vancomycin which should be read through 
transmitted light.The interpretation as susceptible, intermediate and 
resistant were done according to the CLSI guidelines13.(Appendix) 
SREENING TESTS FOR HIGH  LEVEL AMINOGLYCOSIDE  
RESISTANCE (HLAR): 
The Enterococcal isolates were  screened  for high level resistance 
to aminoglycosides using the antibiotic  discs – high  level gentamicin( 
HLG) 120µg and high level streptomycin( HLS) 300µg on Mueller – 
Hinton agar by standard disc diffusion method   as described above 
using McFarland 0.5 turbidity standard  bacterial suspension and 
incubated at37ºC overnight. 
The results interpreted as per CLSI standards13 susceptible  
10mm, inconclusive-7-9mm, resistant – 6mm.The test included   
E.faecalis ATCC29212  as negative control and E.faeciumBM4147 
positive control.The isolates showing zone of inhibition 7-9mm were 
tested again by  agar dilution method using brain heart infusion agar ( 
BHI) containing gentamicin 500µg /ml as recommended by CLSI 
guidelines.10 µl of the bacterial suspension after standardization with 
0.5 Mc Farland Standard  was  spot inoculated onto the agar  and 
incubated aerobically at 35±2ºC for 24-48hrs. in the same way  
Streptomycin 2000 µg/ml was also tested.  The results were interpreted 
as resistant when > 1 colony is observed on the screen agar. 
DETECTION OF  VANCOMYCIN RESISTANCE : 
Presumptive identification of vancomycin resistance  can be done 
by Vancomycin screen agar (i.e) brain heart infusion  (BHI) agar 
containing 6 µg /ml vancomycin. 10µl of 0.5 McFarland suspension of 
the isolate ,along with positive and negative control strains, is spot 
inoculated onto the agar surface and incubated aerobically  for 24hrs at 
35±2ºC.Growth  of > 1 colony indicates presumptive vancomycin 
resistance which should be confirmed by  determining the Minimum  
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inhibitory concentration (MIC) for vancomycin13. The test included   
E.faecalis ATCC29212  as negative control and E.faeciumBM4147 
positive control 
VANCOMYCIN MIC by BROTH  MICRODILUTION  METHOD14: 
The minimum inhibitory concentration of  vancomycin for the 
Enterococcal isolates  grown on vancomycin screen agar were  done as 
per the CLSI recommendations14,44.  
Preparation  of  drug concentrations of  vancomycin; 
Stock solution is prepared as recommended in CLSI document on 
dilution testing14.The vancomycin  drug is dissolved in distilled water 
and the master dilution is prepared by  diluting the required amount of 
drug  in Cation adjusted Mueller-Hinton broth(CAMHB)  (MHAbroth 2 
).  Serial doubling dilution of the master dilution was perfomed in cation 
adjusted Mueller – Hinton broth .Thus the  following concentrations of 
vancomycin 0.5µg /ml, 1, 2, 4, 8, 16, 32, 64, 128, 256, 512, 1024, 
2048µg/ml are prepared using CAMHB broth.  
Bacterial Inoculum preparation : 
Bacterial  inoculum is prepared by  Direct Colony Suspension 
method , and standardized with 0.5 McFarland standard. 1 in 100 
dilution of this inoculum is prepared by adding  0.01 ml of this to 0.9 ml  
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of CAMHB.  10 µl of this diluted suspension is equivalent to  the   final 
recommended inoculum of  5×104   CFU/ml , dispensed per well. 
The serial doubling dilution of vancomycin  already prepared is 
dispensed in 100µl amounts in the respective wells  with a growth 
control( well containing CAMHB broth and bacterial inoculum, without 
vancomycin ) and a sterility control ( well containing CAMHB broth 
only). To this 10µl of  bacterial inoculum was added to all wells  except  
sterility control well and the plates were incubated  at 35±2 ºC for 24 hrs 
in ambient air. The test included   E.faecalis ATCC 29212  as negative 
control and E.faeciumBM4147 positive control QC strains. 
Minimum inhibitory concentration  ( MIC)  is the minimum 
concentration of the drug showing complete inhibition of  bacterial 
growth visible to the naked eye. Results were interpreted after reading 
the MIC  of   QC strains which should fall within the recommended 
range.  The  MIC range of E.faecalis ATCC 29212 should  fall within the 
range of 1-4µg/ml .The  MIC of other isolates were interpreted as per 
CLS I guidelines14. 
 
 
MIC  MINIMUM INHIBITORY CONCENTRATION  FOR 
TEICOPLANIN:  
The  glycopeptide  teicoplanin MIC was also tested in the same  
method as described above .The concentrations of Teicoplanin prepared 
were o.065µg/ml -0.125.0.5,1,2,4,8,16,32,64,128,256µg/ml  by 
dissolving the teicoplanin in CAMHB broth in the same way as 
described in the CLSI guidelines14. 
The bacterial inoculum is prepared  by direct colony suspension 
method  and standardized with 0.5 McFarland turbidity standard. From 
this 1in 100dilution of the bacterial inoculum is prepared in the same 
way as described above.  About 100µl  of each  drug concentration  
dispensed in to the wells of microtitre plate leaving the growth control 
well.10µl of the final inoculums is dispensed into all these wells except 
sterility control well. The plates were incubated at 37ºC for 24 hrs.  
The MIC results were interpreted by noting the minimum 
concentration of the drug showing complete inhibition of the growth of 
the organism in the same way as described for Vancomycin. 
 
 
    
MOLECULAR METHOD  FOR THE DETECTION OF  VRE:  
  Polymerase chain reaction (PCR) assay was performed  by the for 
the detection of  Vancomycin resistance genes in Enterococci especially 
in  E.faecium, and E.faecalis by the  PCR Kit procured from Helini 
Biomolecules,Chennai. The DNA  is extracted from the Enterococcal 
isolates by using Helini Pure Fast Bacterial Genomic DNA Mini Spin 
Prep Kit and subjected to PCR  and the gene product viewed by gel 
electrophoresis. 
Extraction of  DNA  from the  Enterococcal  isolates : 
1. 1.5 ml of overnight bacterial culture was taken and centrifuged at 
12000 rpm at 4º C for 5 min. 
2. To the pellet 180µl of  Lysozyme  digestion buffer was added 
3. To this 20µl of Lysozyme was added  and incubated for 10 min at 
37 ºC. 
4. Then 200µl of Lysis buffer was added. 
5. Then20l of proteinase K was added  mixed well and incubated  
at  56ºC for 15 minutes in a waterbath 
6. To this 200µl of Isopropanol was added and mixed well by 
inverting several times. 
7. The entire volume of sample was transferred to Pure fast spin 
column using pipette and centrifuged for1min at 10,000rpm. 
8. 500µl of wash buffer added to the spin column and centrifuged for 
30 seconds  and the flow-through was discarded , the spin column 
is placed back in collection tube. 
9. Washing repeated  twice using wash buffer II. 
10. The flow- through is discarded  mini spin  centrifuged for 1 min to 
remove residual ethanol. 
11. The spin column is placed in a fresh centrifuge tube  and 50µl of 
pre warmed Elution buffer was added  to the spin column , 
incubated for 2 min at room temperature , then centrifuged for 1 
min. 
12. Then the spin column is discarded DNA present in the centrifuge 
tube is stored at at -20º C. 
5µl of this elute was used for PCR.    
PCR  master mix  consists of dNTP mix 20Nm,Taq buffer and  Taq 
polymerase enzyme 
 The Van A Primers designed by Gautham Pulavar, Helini 
Biomolecules, are  as follows. 
Forward Primer: 5’ -TGCGCGGAATGGGAAAACGACA-3’  
Reverse Primer: 5’ -CAGCCCGAAACAGCCTGCTCAA-3’  
The PCR Product size is 473bp representing Van A gene. 
 An optimal negative control was employed using 1 µl  molecular grade 
water. 
 PCR  amplification :  
The PCR  reactant mixture for each sample is  prepared by adding  
20l of PCR Master Mix, 2l  of Van A Gene specific Primer mix , 5l 
of Purified DNA of each sample and 3l of Nuclease free water to a  
total final volume of  30l.PCR amplification was performed in thermal 
cycler (MyGenie, Bioneer,South Korea) using the following thermal 
profile which consists of one cycle of initial denaturation at 95ºC  for 
4min followed by 35 cycle of denaturation at 95ºC for 30sec, primer 
annealing at 62ºC for  30sec, extension at 72ºC – 30sec  and one cycle of 
Final extension at 72ºC for 5min. 
Analysis of PCR product was done  by agarose gel 
electrophoresis. 
About 1.5% of  agarose gel was prepared by  mixing  0.75 grams of 
agarose powder in 50 ml of electrophoresis buffer and  heated in  a 
microwave oven till agarose is uniformly dissolved. After cooling to 
56ºC, 5µl of Ethidium bromide was added using gloved hands. Ethidium 
bromide is carcinogenic and hence should be handled with gloved hands 
and the tip is discarded into the black bin. After cooling the solution, it is 
poured into a gel casting tray containing comb and allowed to solidify. 
After  hardening , the gel is placed in the electrophoresis tank. The 
electrophoresis buffer provided in the kit is diluted ten times and is 
poured into the tank till the gel is completely immersed, then the comb 
was carefully removed.  Then the electrical leads were connected  to the 
electrophoresis tank. About 15µl  of loading buffer containing the PCR 
product and the tracking dye  is loaded into each well using 
micropipette. About 10µl of 100 bp DNA ladder was loaded into the 
first well followed by 15µl of the sample in the other wells. A constant 
current of 100 volts was applied and the gel is allowed to run till the 
tracking dye reaches three fourth of the gel. 
Then the  gel tray is removed from the tank . Then the gel is 
removed from the tray and placed in the UV transilluminator  for  
observation of  bands  of 473 bp size . 
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OBSERVATIONS AND RESULTS: 
This study was carried out in the department of Microbiology 
during the 18 month period from July 2011 to November 2012 . A total 
of about  8774 urine specimens,6305 pus specimens, 3655 blood 
specimens,2183  tissue fluid specimens and 128 feces specimens were 
analyzed for Enterococcal growth. The results were analyzed as follows.  
A   total of about  240 Enterococcal isolates were recovered from 
the above samples, of which majority were from urine specimens-211, 
13 from blood specimens, 8 from pus specimens , 2  from tissue fluids 
(bile, Bronchial secretion) and 6 isolates from feces specimens. 
 
 
 
 
 
 
 
Table .1.Distribution  of  samples showing growth of Enterococci 
Specimen 
type 
OP IP Total 
No of 
samples 
analyzed 
Positive for 
Enterococcal 
growth 
No of 
samples 
analyzed 
Positive for 
Enterococcal 
growth 
No of 
samples 
analyzed 
Positive 
for 
Enterococ
cal 
growth 
Urine 4169 113 (2.7%) 4605 98 (2.1%) 8774 211  ( 2.4%) 
Pus 586 - 5719 8(0.001%) 6305 8 (0.001%) 
Blood 319 - 3336 13 (0.003%) 3655 13   (0.003%) 
Tissue 
fluids 3 - 2180 2  (0.009%) 2183 
2  
(0.009%) 
Feces 60 - 68 6   (8.8%) 128 6   (4.6%) 
Total 5137  (24%) 113 (2.1%) 
15908 
(76%) 127 (0.007%) 21045 
240 
(1.1%) 
OP- outpatients,    IP – inpatients 
               The majority of the specimens were from inpatients (76%) than 
from outpatients(24%) . Majority of the Enterococcal isolates were from 
urine specimens 211 (87%) , followed by blood (5%),pus (3%) tissue 
fluids (0.8%),feces(4.6%).  
 
 
Table 2: Distribution of Enterococcal isolates  
Specimens ICU/ IMCU 
 
Non ICU Total 
  nephrology urology surgery medicine pediatrics  
Urine 9 11 92 12 38 47 211 
Blood 4 - - - 7 2 13 
Pus - - - 8 - - 8 
Tissue 
fluids 1 - - - 1 - 2 
Feces - - - - 4 2 6 
Total 14(6%) 11(4.5%) 92(38%) 20(8%) 50(21%) 51(21%) 240 
 
ICU-
14(6%) 
Non ICU –226( 94%) 
 
 
 
ICU- Intensive care units, IMCU-Intensive medical care unit.A total of 
14 (6%) Enterococci isolates were from intensive care units (medicine, 
surgery). The isolates from various specialties were 11(4.5%)  from 
nephrology, 92(38%) from urology, 20(8%) from surgery , 50(21%) 
from medicine , 51(21%) from pediatrics.  

Figure 1 .DISTRIBUTION OF SPECIMENS POSITIVE FOR 
GROWTH OF ENTEROCOCCUS SPP. 


Figure 2 DISTRIBUTION OF ENTEROCOCCAL GROWTH 
AMONG DIFFERENT SPECIALITIES 
Table 3.Age and sex distribution of Enterococcal isolates .(n-240) 
Age 
sex 
Total 
Male Female 
Adults( 13yrs) 75  (40%) 114 (60%) 189 (79%) 
Children(12yrs) 27 (53%) 24 (47%) 51 (21%) 
Total 102 (43%) 138 (57%) 240 
 
 Out of  the total 240 Enterococci isolated, majority were isolated from 
adult patients189  (79%),however around 51( 21% )of isolates from 
pediatric patients.  
 
 
 
 
 
 
 

Figure 3 Distribution of Enterococcal isolates among male and 
female patients 
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Figure 4 Distribution of Enterococcal Growth among Adults & 
childrens 
Table 4. Distribution of different  Enterococcal species  among the 
specimens. 
Enterococcal  
Species Urine Blood Pus 
Tissue 
fluids Feces 
Total 
no 
Prevalence 
value per 
100subjects 
E.faecalis 115 6 2 - 3 126 (52.5%) 52.5% 
E.faecium 72 5 2 2 3 84 (35%) 35% 
E.raffinosus 8 - - - - 8(3%) 3% 
E.sulfurous 5 - - - - 5(2%) 2% 
E.columbae 3 1 - - - 4(1.6%) 1.6% 
E.CDC 
PNSE2 3 - - - - 3(1.2%) 1.2% 
E.durans 1 - 1 - - 2(0.8%) 0.8% 
E.hirae 2 - - - - 2 (0.8%) 0.8% 
E.dispar 1 1 - - - 2(0.8%) 0.8% 
E. asini 1 - 1 - - 2(0.8%) 0.8% 
E.avium - - 1 - - 1(0.4%) 0.4% 
E.mundtii - - 1 - - 1(0.4%) 0.4% 
Total 211 13 8 2 6 240  
 
E.faecalis is the predominant species followed by E.faecium. Other  
Enterococcal species such as E.sulfurous, E.columbae , have been  
isolated from urine samples and E.columbae,E.dispar from 
blood,E.mundtii,E,asini,E.avium and E.durans from pus samples . 
 

Figure 5. Distribution of different Enterococcal species among the 
specimens 
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Table 5. Antibiotic susceptibility pattern of Predominant 
Enterococcal species by Kirby-Bauer disc diffusion method. 
Enterococal 
species 
Tot
al 
no 
Penicillin G Ampicillin Doxycycline ciprofloxacin 
High level 
Streptomycin 
High level 
gentamicin 
Vancomycin 
  S R S R S R S R S R S R S R 
E.faecalis 126 
11 
9% 
115 
91% 
110 
87% 
16 
13% 
45 
36% 
81 
64% 
14 
11% 
112 
89% 
82 
65% 
46 
35% 
68 
54% 
58 
44% 
122 
97% 
4 
3% 
E.faecium 84 
11 
1% 
83 
99% 
18 
21% 
66 
79% 
27 
32% 
57 
68% 
7 
8% 
67 
92% 
51 
61% 
33 
39% 
26 
31% 
58 
69% 
62 
74% 
22 
26% 
E.raffinosus 8 
0 
0% 
8 
100
% 
3 
38% 
5 
62% 
 
7 
88% 
1 
22% 
5 
62% 
3 
38% 
4 
50% 
4 
50% 
7 
88% 
1 
22% 
7 
88% 
1 
22% 
E. sulfurous 5 
2 
40% 
3 
60% 
3 
60% 
2 
40% 
5 
100% 
0 
0% 
2 
40% 
3 
60% 
5 
100
% 
0 
0% 
5 
100% 
0 
0% 
5 
100% 
0 
0% 
E.durans 3 
2 
67% 
1 
33% 
3 
100% 
0 
0% 
3 
100% 
0 
0% 
2 
67% 
1 
33% 
2 
67% 
1 
33% 
3 
100% 
0 
0% 
3 
100% 
0 
0% 
E.CDC PNSE2 3 
2 
67% 
1 
33% 
3 
100% 
0 
0% 
2 
67% 
1 
33% 
1 
33% 
2 
67% 
2 
67% 
1 
33% 
2 
67% 
1 
33% 
2 
67% 
1 
33% 
 
The results were interpreted by measuring the zone of inhibition of 
growth around each disc as per CLSI guidelines13.  Most of  E. faecalis  
isolates  are resistant to penicillins (91%)  but preserve sensitivity to 
ampicillin(87% - sensitive), susceptibility to doxycycline is around 36% 
and ciprofloxacin 11%.The E .faecium  isolates are  resistant to 
penicillin(99%), ampicillin (79%) doxycycline(68%) and ciprofloxacin 
(92%). 
Table 6.HLAR  (High Level Aminoglycoside Resistance) among 
E.faecium and E.faecalis isolates by Disc diffusion method 
Enterococcal 
species 
Total 
isolates 
Resistant to 
both HLG 
(120µg) & 
HLS(300µg) 
Resistant 
to HLS 
only 
Resistant 
to HLG 
only 
Total 
HLAR 
E.faecalis 126 18 37 31 86( 68%) 
E.faecium 84 24 33 11 68(80%) 
Total 210 42(20%) 70(33%) 42(20%) 154(73%) 
HLG-high level Gentamicin(120µg),HLS-high level Streptomycin 
(300µg) 
Pvalue for E.faecalis HLAR -86/126 = 68 per 100 subjects,  Pvalue for 
E,faecium HLAR -68/84 = 80 per 100 subjects 
     The results were interpreted  by measuring the zone of inhibition 
around the antibiotic disc as per CLSI guidelines13 . The total  HLAR- 
high level aminoglycoside resistance observed  is 73% and resistance to 
both agents observed in a total of  42 isolates (20%) and resistance to 
streptomycin only is  observed in a total of70 isolates (33%) and 
resistance to gentamicin only is observed in42 isolates (20%).The 
HLAR is observed in  E.faecalis isolates was  68% and about 80% in 
E.faecium.    
          Then all the 240 Enterococcal isolates( irrespective of the 
susceptibility pattern of vancomycin by  disc diffusion method),  were 
screened on vancomycin screen agar(  containing  vancomycin 6µg/ml)  
for presumptive identification of vancomycin resistance. About 29 
isolates showed growth indicating  resistance to vancomycin.These 29 
isolates were subjected to  MIC ( Minimum Inhibitory Concentration) 
for vancomycin  as a confirmatory test. Of these 29 isolates, 8 isolates  
turned out to be susceptible by vancomycin MIC (4µg/ml) and 11 
isolates showed vancomycin MIC  values 8-16µg /ml ,and 10 isolates 
32µg/ml hence interpreted as Vancomycin Resistant Enterococcal 
isolates as per CLSI guidelines14 .(Appendix) 
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Table.7.MIC values of Vancomycin for  the VRE isolates. 
VRE 
isolates 
n-21 
Vancomycin MIC values (µg/ml) 
Total 
Intermediate 
(8-16 µg/ml) 
Resistant 
(32 µg/ml) 
8 
µg/ml 
 
16 
µg/ml 
32 
µg/ml 
64 
µg/ml 
128 
µg/ml 
256 
µg/ml 
512 
µg/ml 
E.faecium 2 6 1 4 2 2 1 18 
E.faecalis - 1 1 1 - - - 3 
Total 2 7 2 4 2 2 1 21 
MIC- Minimum inhibitory concentration 
Out of the total 21 VRE  isolates, the MIC values of 11 isolates fall 
within the intermediate range 8-16µg/ml, and10 isolates fall within the 
resistant range of  32-512µg/ml, interpreted as per CLSI guidelines14 
(Appendix) 
 
 
 
 
 
 
Table 8.MIC values of teicoplanin for the VRE isolates 
VRE 
isolates 
n-21 
Teicoplanin MIC values (µg/ml) 
Total 
Susceptible(8 µg/ml) 
Intermediate 
(16 µg/ml) 
 
Resistant 
(32 µg/ml) 
0.5 
µg/ml 
1 
µg/ml 
2 
µg/ml 
 
4 
µg/ml 
 
8 
µg/ml 
 
 
16 
µg/ml 
 
32 
µg/ml 
 
64 
µg/ml 
 
E.faecium 7 2 - - - 4 4 1 18 
E.faecalis 0 2 - - - 1 - - 3 
Total 7 4 - - - 5 4 1 21 
MIC- Minimum inhibitory concentration 
Out of the total 21 VRE isolates, the teicoplanin  MIC of 11 isolates fall 
within the susceptible range (0.5-1 µg/ml)  and 5 in intermediate range-
16 µg/ml and 5 isolates fall within the resistant range(>32 µg/ml 
interpreted as per CLSI guidelines14 (Appendix). 
 
 
 
 
Table 9.Phenotypic classification of VRE isolates based on MIC  
Interpretation of Vancomycin and Teicoplanin . 
Van phenotype E.faecium E.faecalis Total 
Van A 
vancomycin MIC 64 µg/ml(R)  & 
teicoplanin MIC 16µg/ml(R) 
9(50%) 1 (8.3%) 10(48%) 
Van B 
Vancomycin MIC  8 µg/ml (IM/R) 
& teicoplanin MIC 0.5-1 µg/ml (S) 
9 (50%) 2(15.3%) 11 (52%) 
Total VRE isolates 18(72%) 3 (12%) 21 
 
Prevalence rate of  total VRE (21/240) -  8.75 per 100 subjects. 
          As per the above results, the  vanA phenotype showing resistance 
to both vancomycin(64 µg/ml) and teicoplanin(16 µg/ml ) was  
observed in 10 VRE isolates (10/21) (48%). About  11 isolates belong to 
VanB  (11/21) (52%) (phenotype with vancomycin  MIC 8 µg/ml 
including the intermediate and resistant range and teicoplanin MIC in 
the susceptible range usually (0.5-1 µg/ml) interpreted as per CLSI 
guidelines14,45 (in appendix) 
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         All the 21 vancomycin resistant Enterococcal isolates were 
subjected to PCR assay to detect the presence of Van A gene and the 
results were as follows. 
Table 10. Distribution of Van A Genotype in the VRE isolates 
Enterococcal isolates 
n-21 
Total isolates tested VanA genotype 
present Absent 
E.faecium 18 9 (50%) 9(50%) 
E.faecalis 3 1 (33.3%) 2(66.6%) 
Total 21 10(48%) 11(52%) 
 
Out of the total 21 VRE isolates 1 E.faecalis and 9 E.faecium isolates 
were of vanA genotype showing bands of 473bp as per the PCR assay 
for vanA gene . The remaining 11 VRE isolates did not show any band 
corresponding to vanA gene They should be evaluated further to assess 
their genotype. 
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Table 11. The correlation of MIC values of vancomycin and 
teicoplanin with Genotyping for Van A gene . 
VRE 
isolates 
No of 
isolates 
MIC for 
Vancomycin  
µg/ml 
MIC for 
Teicoplanin 
µg/ml 
Presence of 
van A gene 
E.faecium 9 64- 512 µg/ml 16-64µg/ml 9 
E.faecalis 1 64 µg/ml 16 µg/ml 1 
Total 10 64µg/ml 16 µg/ml 10 
 
 About 9 E.faecium isolates and  1 E,faecalis shows High level 
resistance to both Vancomycin and Teicoplanin and are of VanA 
phenotype 
 Thus there is 100% concordance of phenotypic classification by 
Vancomycin MIC and genotypic detection of the VanA resistance type.   
 
 
 
 
 
Table . 12- Antibiotic susceptibility pattern of VRE isolates to 
supplemental drugs by Kirby- Bauer disc diffusion method. 
Enterococcal 
species 
Total no LZ CK RP 
  S 
 
R S R S R 
E.Faecalis 3 3 
100% 
0 
0% 
0 
0% 
3 
100% 
NA NA 
E.faecium 18 
 
18 
100% 
0 
0% 
7 
39% 
11 
61% 
18 
100% 
0 
0% 
Total 21 21 
100% 
0 
0% 
7 
33% 
14 
67% 
 
18 
100% 
0 
0% 
 
LZ-Linezolid, CK-chloramphenicol, RP-pristinamycin (Quinupristin / 
Dalfopristin),  NA- not applicable( E.faecalis is inherently resistant to 
Q/D). 
All of the VRE isolates were susceptible to Linezolid(100% sensitivity), 
whereas the 3 E.faecalis were resistant to  chloramphenicol . Out of the 
18 E.faecium VRE isolates, 11(61%) showed resistance to  
chloramphenicol  and all of the E. faecium VRE isolates were sensitive 
to Quinupristin/Dalfopristin. 
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
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DISCUSSION: 
Enterococci are emerging as one of the most common agents of 
nosocomial infections in the hospital and also cause opportunistic 
infections in immunocompromised individuals6,7,11. It is a well known 
fact they can cause a variety of serious life threatening infections like 
endocarditis, bloodstream infections and also cause wound infections , 
urinary tract infections6,7,44. Their survival ability under adverse 
environmental conditions  along  with the property of intrinsic and 
acquired resistance to a variety of  antibiotics  make them the difficult 
pathogen to treat with significant mortality and morbidity7. Hence it is 
essential to detect them early and institute proper therapy based on the 
antimicrobial susceptibility pattern.  With the emergence of  
Vancomycin Resistant Enterococci (VRE), the situation has  worsen 
leaving very few options of selecting antibiotics  for the treatment of this 
multi – drug resistance organism. At  this context, our study has been 
attempted to assess the prevalence of vancomycin resistance among the 
clinical isolates of Enterococci recovered from the patients in this area.  
A   total of about  240 Enterococcal isolates were recovered from  
a total of  about 21,045 clinical samples   including urine , blood ,pus. 
The majority of the specimens were from inpatients (76%) than from 
outpatients(24%)  which is in correlation  with the findings of Acharya1 
et al,who have  reported 72% specimens from hospitalized patients and  
28% specimens from outpatients. 
In our study,   majority of the Enterococcal isolates were from 
urine specimens 211 (87%) , followed by blood (5%),pus (3%) tissue 
fluids (0.8%),feces(4.6%).which is  higher  than  the findings of 
V.Gupta. et al46. who have reported Enterococcal isolation rate of 49% 
from urine,5% from blood 
In this study , a total of 14 (6%) Enterococci isolates were from 
intensive care units (medicine, surgery).  Suzanne.L.F et al41.  have 
reported 13.9% of Enterococcal isolates from ICU and 12% from non 
ICU patients . In our study, the isolation rate from  ICU patients  is 
lower about 6%. The risk factorswe  observed in ICU patients  were 
presence of  intravenous catheters , one patient on endotracheal 
intubation,two patients were transplant recipients under 
immunosuppression,one patient on urinary catheterization, presence of 
comorbid conditions such as Diabetes and heart disease,  prolonged 
hospitalization  and broad spectrum antibiotic usage such as third 
generation cephalosporins.From nephrology  3 patients were on chronic 
ambulatory peritoneal dialysis.In the surgical wards, presence of 
comorbid conditions like diabetes, prolonged hospitalization , broad 
spectrum antibiotic usage (third generation cephalosporins, 
metronidazole)were the associated risk factors. The pus samples from 
surgical patients were chronic ulcers,   and discharge from  abdominal 
wound(no drain). In medicine patients comorbid conditions, broad 
spectrum antibiotic usage and recurrent infections were the associated 
risk factors. In pediatric patients, malnutrition and prolonged 
hospitalization were observed. The feces samples were processed as 
surveillance cultures. 
  We also observed that the isolation rate in  patients of medicine 
was  21%,whereas it was  8% from surgery patients and 21% from 
pediatrics  .. The present study showed  varying isolation rates with 
other studies such as  MM. Salem-Bekhit et al39 , who have reported the 
Enterococcal isolation rate of about 85% from ICU, about 27.9% from 
surgical patients and11.3% from internal medicine ward.     
Out of  the total 240 Enterococci isolated, majority were isolated 
from adult patients189  (79%),however around 51( 21% )of isolates 
from pediatric patients. Acharya,A. et al1. have isolated about 30.5% 
Enterococci from pediatric patients a which is in close resemblance to 
our study.  
A   higher isolation rate of  about 57% (138/240) was observed 
among the female patients than 43% (102/240) from male patients. This 
is in contrary to the findings of MM Salem – Behkit et al39. who have 
reported a male preponderance of about 91% in their study. 
In our study we observed that   E.faecalis is the predominant 
species 126 (52.5%) followed by E.faecium 84 (35%) E.raffinosus(3%), 
E.durans(0.8%)  E.hirae 0.8% , E.avium(0.4%) and  E,mundtii (0.4%) 
.In other studies , Perlada.D,et al37. have reported,69%E.faecalis,29% 
E.faecium and 1% each of E.avium and E.durans .Vittal P Prakash et 
al47 have reported 2.5% E.raffinosus and 2.5% E. hirae , 1.7% 
E.mundtii .and MM Salem-Behkit et al39. have reported 2.1% E.avium  
and 0.8% of E.hirae which correlates with the findings of our  study. 
On studying the antibiotic susceptibility  pattern  we found that  
most of  E. faecalis  isolates  are  highly resistant to penicillins (91%)    
but  a higher sensitivity to ampicillin  (87%) .The E .faecium  isolates 
have shown  higher resistance rates to  penicillin(99%), ampicillin 
(79%) doxycycline(68%)  
Agarwal.J2. et al, have reported significantly higher resistance  to 
ampicillin among E.faecium isolates than E.faecalis   similar to our 
study. Multidrug resistance i.e resistance to    penicillin,doxycycline,   
and aminoglycoside, is a common finding in our study among the 
E,faecium  isolates as observed by  the studies of Ghoshal.U et al22. 
(2006) from Lucknow, central India , Agarwal.J  et al2. (2008) from 
Lucknow. 
  As per our study,the total  HLAR- high level aminoglycoside 
resistance observed  is 73%.The HLAR is observed in  E.faecalis 
isolates was  68% and about 80% in E.faecium. Our finding is similar to 
the report by Mohanty.S et al33 from north India HLAR rate about  
73.3%  and 77% by Ghoshal.U et al22 from Lucknow. Also resistance to 
streptomycin only is  observed in a total of70 isolates (33%) and 
resistance to gentamicin only is observed in42 isolates (20%) in our 
study  which is a little higher than the reports from MM Salem-Behkit et 
al39 from Saudi Arabia20.9% to gentamicin and 19.4% for streptomycin.  
  Out of  the240 Enterococcal isolates, the29 isolates(12%) which  
were identified presumptively  as vancomyin resistant on vancomycin 
screen agar containing  vancomycin 6µg/ml  were subjected to  MIC ( 
Minimum Inhibitory Concentration) for vancomycin  as a confirmatory 
test. Of these 29 isolates, 8 isolates  turned out to be susceptible by 
vancomycin MIC (4µg/ml) and   21 isolates were vancomycin resistant  
with 11 isolates showing vancomycin MIC  values 8-16µg /ml ,and 10 
isolates 32µg/ml   In our study, the MIC  range of  most of theVRE 
isolates  fall within  8-256µg/ml with one isolate showing 
512µg/ml.This was similar to the findings of Patel.Ret al52, from mayo 
clinic, United States,  the vancomycin MIC range of VRE isolates 8-
256µg/ml in their study. Praharaj.I et al38. from South India have 
reported a case report,  van A E.faecalis  with Vancomycin   MIC 
256µg/ml,. 
All the  21 vancomycin resistant  isolates were tested for  MIC of 
teicoplanin  and  11 isolates showed The MIC in the susceptible range 
(0.5-1 µg/ml)  and 5 in intermediate range-16 µg/ml and 5 in resistant 
range(>32 µg/ml ).Thus in our study, the teicoplanin MIC range 
observed was16-64µg/ml which was similar to the report given by  
Patel.R etal52. from mayo clinic with  isolates showing>16 µg/ml and by 
Ghoshal. U et al22 .>16µg/ml in all their VRE isolates. 
  Based on the  MIC of vancomycin and teicoplanin , 10 VRE 
isolates (10/21) (48%) were of  vanA phenotype showing resistance to 
both vancomycin(64 µg/ml) and teicoplanin(16 µg/ml ). The 
remaining11 isolates belong to VanB phenotype  (11/21) (52%) with 
vancomycin  MIC 8 µg/ml and teicoplanin MIC in the susceptible 
range usually (0.5-1 µg/ml).  Thus a  total of about 21(8.7%)of  both 
E.faecium and E.faecalis VRE isolates have been identified in our study. 
Agarwal.J, et al2,  from   have reported a VRE isolation rate of 4.65% in 
E.faecalis in their study . Ghoshal .U et al22. from from Lucknow have 
reported a 1.4% (10/685) VRE isolation ( all were E.faecium) in their 
study which is lower than our study.   
Out of the total 21 VRE isolates 1 E.faecalis and 9 E.faecium isolates 
were of vanA genotype as per the PCR assay for vanA gene . The 
remaining 11 VRE isolates did not show any band corresponding to 
vanA gene. Hence They  may belong to any of  the genotype other than 
vanA. Yasliani .S et al51. have reported in his study 10(58%) vanA 
genoytypes, 6(35%)  VanB genotype(6%) and 1VanC genotype in a total 
of 17 VRE isolates urine, blood and stool. In our study we have isolated 
10( 48%) vanA genotype VRE out  of 21 VRE isolates which is slightly 
lower compared to the above study. There are isolated case reports of 
vanA E,faecalis by Praharaj. I.et al38 from  south India.   Roger 
.M.Faucher et a49l. from Canada  have reported 25% (55/223) vanA 
E.faecium which is little lower rate than our study.  
 About 9 E.faecium isolates and  1 E,faecalis shows High level 
resistance to both Vancomycin and Teicoplanin and are of VanA 
phenotype. Thus there is 100% concordance of phenotypic classification 
by Vancomycin MIC and genotypic detection of the VanA resistance 
type.   Similar to our study, Suzanne et al41  have reported 100% 
concordance of these two methods for the detection of van A VRE. 
Whereas Perlada.D et al52 have reported 95% concordance in their study 
which is  lower than that of our study. 
 On studying the susceptibility pattern of supplemental drugs like 
linezolid, Quinupristin/ dalfopristin and chloramphenicol , all of the he 
VRE isolates were susceptible to Linezolid(100% sensitivity), 
67%showed resistance to  chloramphenicol  and all of the E. faecium 
VRE isolates were sensitive to Quinupristin/Dalfopristin. The study 
carried out by  V,Gupta,et al46, from Chandigarh , India  and MM 
Salem- Behkit et al39.  from Iran have reported, 100% sensitivity of VRE 
isolates  to linezolid which is similar to our study. Perlada.D37.et al, from 
Australia also have reported 100% sensitivity to linezolid and 100 % 
sensitivity to chlramphenicol. But in our study only 39% of isolates were 
sensitive to chloramphenicol. 
 
 
 
SUMMARY: 
 A total of about 21,045 clinical specimens like urine , blood, pus 
and tissue fluids were analyzed for Enterococcal isolates.Majority 
of the specimens were from inpatients (76%) than from 
outpatients. 
 A total of about  240 Enterococcal isolates were recovered from 
these specimens. Majority of the isolates were from urine 87% 
followed by blood 5%and pus 3% fluids (0.8%).  
 A total of about 14 (6%) Enterococcal isolates were from 
intensive care units and the isolation rate from other specialities - 
nephrology 11(4,5%), urology 92(38%), surgery 20 (8%), 
medicine 50 (21%) and paediatrics 51 (21%). 
 Out of the 240 isolates,majority were from adults about  
189(79%)  and 51 (21%) from children.  Higher isolation rate of  
about 57% (138/240) was observed in female patients when 
compared to male patients43% (102/240). 
 E. faecalis  was the predominant  Enterococcal species with an 
isolation rate of about 52.5% in our study, followed by E.faecium 
35%.   
 Other than these two species, E.raffinosus(3%) , E.sulfurous(2%), 
E.durans(0.8%), E.hirae (0.8%) E.avium (0,4%)and E. 
mundtii(0.4%) were also recovered from the clinical specimens. 
 The antibiotic susceptibility pattern showed 99% resistance to 
penicillin,79%to ampicillin, 68% doxycycline resistance in  
E.faecium  isolates and 91% penicillin resistance ,13% ampicillin 
resistance and 64% doxycycline resistance in E.faecalis isolates. 
 The  HLAR- high level aminoglycoside resistance  observed  is 
73% and resistance to both agents observed in a total of  42 
isolates (20%) and resistance to streptomycin only is  observed in 
a total of70 isolates (33%) and resistance to gentamicin only is 
observed in42 isolates (20%). 
 The High Level Aminoglycoside Resistance was higher in 
E.faecium isolates 80% (68/84) than E.faecalis isolates 86/126(68 
%). 
 About 29 isolates (12%) were presumptively identified as 
vancomycin resistant by vancomycin screen agar containing 6 
µg/ml vancomycin.  
 All  the 29 isolates were tested for Minimum Inhibitory 
Concentration(MIC) of vancomycin by microbroth dilution 
technique  which showed  8 isolates to be vancomycin susceptible 
( MIC values 4µg/ml) and 21 isolates with vancomycin  MIC 
range of 8µg/ml  ( 11 isolates in  intermediate range  8-16 µg/ml 
and 10 isolates in resistant range 32µg/ml), 
 The  highest MIC  value observed being 512µg/ml by E.faecium 
isolated from pus specimen from a patient with pseudocyst of 
pancreas. The other VRE isolates - one E.faecium from blood 
sample of a patient with heart disease with suspected  infective 
endocarditis ,one E.faecium from bronchial secretions in a patient 
with suspected carcinoma bronchus,  1 E.faecium and 1 E,faecalis  
from pus(leg ulcer, ear discharge) and the remaining isolates 
2E.faecalis and14 E.faecium  from urine specimens from patients 
with comorbid conditions like diabetes,hypertension and 
decompensated liver disease.feces samples were  negative for 
VRE. 
 The commonly associated risk factors  observed in these VRE 
patients were broadspectrum antibiotic usage especially third 
generation cephalosporins and metronidazole , longer duration of 
hospital stay, presence of implants  such as endotracheal tube and 
presence of comorbid conditions like Diabetes, Hypertension and 
heart disease.    
 The MIC testing  of Teicoplanin  by microbroth dilution technique  
for these 21 isolates (to assess the Vancomycin Resistance 
Phenotype- VanA,VanB,VanC, Van D, VanE and VanL)  showed 
-11 isolates  were susceptible to teicoplanin  (MIC 0.5-1µg /ml)  
and 10 isolates were resistant  16µg/ml. 
 About 10 VRE isolates showed MIC 64µg/ml for Vancomycin 
and 16µg/ml for teicoplanin and are identified as of VanA 
Phenotype28,44.   
 The remaining 11 isolates showed Teicoplanin MIC in the range 
of 0.5-1µg/ml and thus belong to VanB Phenotype28,44.  
 Hence the total VRE isolates as per vancomycin MIC values were 
21 and thus the prevalence rate was  8.7% (21/240) .   
 All the 21 VRE isolates were subjected to detection of 
Vancomycin Resistance gene - Van A  by Polymerase Chain 
Reaction.  
 As per the PCR results, a total of  10 isolates including  9 
E.faecium  and  one E.faecalis were found to be of VanA 
Genotype, which were identified as vanA phenotype by MIC of 
vancomycin and teicoplanin.   
 Thus in our study  we found  100% concordance  between  
Phenotypic classification by Vancomycin MIC detection and  
molecular  genotyping  for the detection of Van A type of VRE.   
 All the 21 VRE isolates were  sensitive to Linezolid  and11  
(39%) were sensitive to chloramphenicol. All the 18 vancomycin 
E.faecium were sensitive to Quinupristin and Dalfopristin.   
  
 
 
 
 
 
 
 
 
 
 
CONCLUSION: 
            Enterococci are emerging as an important pathogen causing 
variety of hospital acquired nosocomial infections and also cause 
community acquired infections contributing significantly to patients 
morbidity and mortality. The emergence of vancomycin resistant 
Enterococci worsens the problem further because of the multidrug 
resistance exhibited by these agents leaving fewer therapeutic options 
for the clinicians in treating the serious life threatening VRE infections. 
In our study we isolated a total of 240 Enterococcal isolates from 
various clinical samples with Enterococcus faecalis and Enterococcus 
faecium as  the predominant species . Of these 21 isolates were 
identified as Vancomycin Resistant Enterococci with a prevalence rate 
of about 8.7%  as per  Vancomycin MIC and  the prevalence of  VanA  
genotype VRE is 4.1%  by PCR assay in this region. They showed 
resistance to multiple antibiotics like penicillin, ampicillin, doxycycline 
and exhibited higher rate of high level aminoglycoside resistance. The 
Enteroccocal isolates presumptively identified by vancomycin screen 
agar should be confirmed by determining the minimum inhibitory 
concentration for vancomycin. The phenotyping of VRE isolates  
performed by detection of MIC for both vancomycin and teicoplanin 
correlates well with the genotypic method of  detection of vancomycin 
resitance geneVanA. Thus this method can be adopted in resource 
limited settings (where the genotyping may not be available) for the 
detection of  Vancomycin resistant phenotype of Enterococci.  
            This  emphasizes the need for conducting  frequent surveillance 
programmes for  prompt identification of VRE in hospitals and 
community. This also emphasizes the need for implementation of 
stringent infection control measures  like rational use of antibiotics 
especially restricting the use of  Vancomycin to minimum, proper 
containment and effective treatment of VRE infections, strict hand 
washing practices,  education of the healthcare workers and  other 
personnel involved in the patient management. These measures are to be 
strictly followed to bring down the mortality and morbidity associated 
with these  nosocomial VRE infections. 
 
 
 
 
 
APPENDIX 
Blood agar: 
Ingredients  
Sterile sheep blood  -5 ml 
Nutrient agar          -100 ml 
 Autoclave the nutrient agar  base at 121º C for 15 minutes. Cool 
to 45-50º C and add blood with sterile precautions and pour into Petri 
dish plates. 
MacConkey Agar 
Ingredients                                          Grams/litre 
Peptic digest of animal tissue   -             17 
Proteose peptone                      -               3 
Lactose                                     -              10 
Bile salts                                   -              1.5 
Sodium chloride                        -              5 
Neutral red                                -             0.03 
Agar                                          -             15 
Final  pH at (25º C)    7.1±0.2. 
 Suspend 51.53 grams in 1000 ml of distilled water. Heat  to 
boiling to dissolve the medium completely. Sterilize by autoclaving at 
15 lbs pressure (121ºC) for 15 minutes. Mix well and pour into petri dish 
plates. 
Mueller Hinton Agar: 
Ingredients  
Beef infusion                    - 300 g/l 
Casein acid hydrolysate   - 17.50 g/l 
Starch                                 -1.50 g/l 
Agar                                   -17.00 g/l 
Final  pH at 25º C     7.4. 
 Suspend 38 gms in 1000 ml of distilled water. Heat  to boiling to 
dissolve the medium completely. Sterilize by autoclaving at 15 lbs 
pressure (121ºC) for 15 minutes. Mix well  and  pour  20-25 ml of it into 
petri dishes of  90 mm diameter to a depth of 4 mm of medium. 
 
Bile Esculin Agar: 
Ingredients : 
Peptone            - 5 gm 
Beef extract      -3gm 
Oxgall(bile)       -40gm 
Esculin             -1gm 
Ferric citrate   -0.5gm 
Agar                  -15gm 
Distilled water    -1 L 
pH     7.0 
heat to dissolve the contents completely, sterilize at autoclave at 121ºC 
for10 minutes, pour into slants/ petri plates. 
6.5% NaCl  broth: 
Nutrient broth            - 1L 
NaCl                           - 6.5gm 
Dissolve the contents completely , autoclave at 121ºc for15 min  and 
distribute in tubes. 
Brain -Heart infusion agar: 
Ingredients : 
Agar                                   - 15gm 
Bran heart infusion broth    -1L 
 pH    7.4 
Dissolve the agar completely by boiling . autoclave at 121ºc for 15 min. 
cool to about 50ºC and pour into petri dish plates. 
Vancomycin Screen agar: 
Ingredients : 
Agar                                    - 15gm 
Brain heart infusion  broth  - 1 L 
Vancomycin                     - 6mg/L 
Prepare Brain heart infusion agar  as described above , cool to 50ºC  and 
add 
Vancomycin 6µg/ml , mix well and pour into petri dish plates. 
 
Cation  Adjusted Mueller –Hinton  broth: ( MHA broth  2) ( Himedia 
lab). 
Cation adjusted Mueller- Hinton broth base    - 21 gm 
Distilled water                                                   -1L 
 Dissolve the contents by boiling  and sterilize by autoclaving  at 121ºC 
for 15 min. 
 
 
 
 
 
 
 
 
 
TABLE. 1.ZONE DIAMETER INTERPETIVE STANDARDS FOR 
ENTEROCOCCUS SPP. 
Antimicrobial agent Disk 
content  
Zone diameter 
R              IM              R 
Penicillin G 10units 14 - 15 
Ampicillin  10µg 16 - 17 
Erythromycin  15µg 13 14-22 23 
Ciprofloxacin  5µg 16 16-20 21 
Doxycycline  30µg 12 13-15 16 
HLS – high level  
gentamicin 
120µg 6 7-9 10 
HLG- high level  
streptomycin 
300µg 6 7-9 10 
R-resistant, IM-intermediate  S – sensitive 
Table 2 MIC Interpretive standards 9µg/ml for Enterococcus spp.  
ANTIMICROBIAL AGENT MICµg/ml 
INTERPRETIVE STANDARD 
 S I R 
Vancomycin  4 8-16 32 
Teicoplanin  8 16 32 
    

Vancomycin  30µg 14 15-16 17 
Teicoplanin  30µg 10 11-13 14 
Chloramphenicol  30µg 12 - 18 
Linezolid  30µg 20 - 23 
Quinupristin/ 
dalfopritin 
15µg 15 16-18 19 
BIBLIOGRAPHY: 
 
1. Acharya.A,Khanal.B, Kanugo.R et.al. Characterization and 
susceptibility patterns of clinically important Enterococcus 
species in Eastern Nepal.Indian J. Med. Res 2004. 4 (2)45-8. 
2. Agarwal.J, Kalyan.R , Singh.M, High level Aminoglycoside 
resistance and -lactamase production in Enterococci at tertiary 
care hospital in India, Jpn.J.Infect.Dis. 2009,62.158-159. 
3. Agarwal VA,Jain YI, Pathak AA, Concomitent high level 
resistance to Penicillin and Aminoglycosides in Enterococci at 
Nagpur Central India. Indian .J  Med.Microbiol.1999:17:85-7. 
4. Anonymus, Recommendations for preventing the spread of 
Vancomycin Resistance. Recommendations of Hospital Infecion 
Control Practices Advicery Board Committee (HICPAC). 
MMWR 1995:44(RR-12):1-13. 
5. Anton Mak, Miller.A M, Chong.G et al.Comparison of PCR and 
culture for screening of Vancomycin resistant Enterococci; highly 
disparate results for VanA and VanB. J.Clin Microbiol. 2009, 
p4136-37. 
 
6. Arias.A .C, Murray B.E, Enterococcus species , Streptococcus 
bovis group and Leuconostoc species.In Mandell Band D, editor. 
Principles and Practices of Infectious Diseases. 7th ed. 
Philadelphia; Churchil Livingstone.p 2643-53. 
7. Arias.A .C, Murray B.E . Enterococcal Infections. In :Principles 
of Internal Medicine, Harrisons editor.18th ed. Mc Graw Hill 
Medical. 
8. Betty . A,Forbes, Daniel.F Sahm, Diagnostic Microbiology Bailey 
and Scotts12 th edi. Mosby,Elsevier. 
9. Ballard,S.A, K.K Pertile, M,Lim et al. Molecular characterization 
of VanB elements in naturally occurring gut anaerobes.2005 
.Antimicrob.Agents. Chemother, 49;1688-94. 
10. Bhat KG, Paul C, BhatMg, Neonatal bacteremia due to high level 
Aminoglycoside resistancetEnterococci. Indian.J.Paediat 
1997;64:537-9 
11. Cetkinya. Y, Falk.P, Mayhall CG. Vancomycin –Resitant 
Enterococci, Clin. Microbiol Rev,2000:13: 686-707. 
12. Centers for Disease Control and Prevention. National Nosocomial 
Infection Surveillance (NNIS) system report. Data summary from 
January 1997- April 2000. Am J Infect. Control 2000,28;429-448. 
13. Clinical and Laboratory Standards Institute (CLSI), (formerly 
NCCLS). Performance standards for antimicrobial disk 
susceptibility tests Vol 28 (1).Approved Standard-Ninth edition 
M2-A9 ,2008. Wayne, PA. 
14. Clinical and Laboratory Standards Institute (CLSI), (formerly 
NCCLS). Methods for dilution antimicrobial susceptibility tests 
for bacteria that grow aerobically, Approved standard – seventh 
edition, vol 28(1).M7-A7. 2008, Wayne, PA. 
15. Clark,N.C, R.C.Cooksey, B.C Hill et. al,1993. Characterization of 
glycopeptide resistant Enterococci from U.S hospitals.Antimicrob. 
Agents Chemother.37:2311-2317. 
16. Colles JG, Miles RS, Wan B.Tests for the identification of 
bacteria. Mackie and McCartney Practical Medical Microbiology. 
14th ed.Edinburg, Churchil Livingstone.1996; 131-50. 
17. Desai.PJ, Pandit.D,MathurM et al,prevalence,identification and 
distribution of various species of Enterococci isolated from 
clinical specimens with special reference to urinary tract 
infections in catheterized patients . Indian J Med Microbiol.2001 
19(3)p,132-137. 
18. Dutka-Malen S, Evers S, Courvalin P,Detection of Glycopeptide 
resistance genotypes and identification to the specie level of 
clinically relevant Enterococci by PCR. J Clin Microbiol 
1995;33:24-7. 
19. Dutka-Malen S,Leclercq R,Coutant V  et al,Phenotypic and 
genotypic heterogeneity of Glycopeptide determinants in Gram 
Positive bacteria.Antimicrob Agents Chemother 1990:34:1875-9. 
20.  Faklam RR, Collins MD,Identification of Enterococcus species 
isolated from human infections by  a Conventional test scheme. J 
Clin Microbiol 1989:27:731-4. 
21. Giridhara Upadhyaya PM, Ravikumar KL, Umapathy Bl. Review 
of virulence factor of Enterococcus : An emerging nosocomial 
pathogen.Indian J Med Microbiol 2009:27:301-5. 
22. Ghoshal.U, Garg.A,Tiwari.DP et al.Emerging Vancomycin 
Resistance in Enterococci in India.Indian J Pathol 
Microbiol,2006;49: 620-22. 
23. Hall LMC, Recent advnces in understanding the epidemiology of 
Enterococci.Rev Med Microbiol, 4,;192-7. 
24.  Jan M bell, Paton JC,Turnidge J. Emergence of vancomycin 
resistant Enterococci in Australia: Phenotypic and genotypic 
characteristics of isolates.J Clin Microbiol 1998;36:2187-90. 
25. Kariyama R, Mitsuhata R, Chow JW et al, Simple and reliable 
multiplex PCR assay for surveillance isolates of Vancomycin 
Resistant Enterococci.J Clin Microbiol 2000;38:3092-5. 
26. Kamarkar .G, Gershom. E.S, Mehta P.R.Enterococcal infections 
with special reference to phenotypic characterization and drug 
resistance.Indian J Med Res.2004;119(S), 22-25. 
27. Khan S.A, NawasM.S, Khan A.A et al. Molecular characterization 
of multi drug resistant Enterococcus spp. from poultry and dairy 
forms Detection of virulence and vancomycin  resistance  gene 
markers by PCR. Mol Cell Probes 2004;20; 1-8. 
28. Koneman .E .W,.Gram-Positive Cocci – part II, In: Colour Atlas 
and  Textbook of Diagnostic Microbiology. 6th ed. Lippincott . 
Philadelphia, NewYork. 
29. Lata Kapoor, V. S. Randhawa, Manorama Deb, Antimicrobial 
resistance of  Enterococcal blood isolates at a Paediatric care 
hospital in India.Jpn J Infect Dis.,2005;58:101-103. 
30. Louis. B.Rice, Emergence of vancomycin resistant Enterococci. 
mhtml:file://F:/Vancomycin resistant enterococci/CDC. 
 
31. Mendiratta. D, Kaur  H, Deotale V, et al,Status of high level 
aminoglycoside resistant Enterococcus faecium and Enterococcus 
faecalis   in a rural hospital in central India. Indian J Med 
Microbiol 2008;26:369-71. 
32. Mathur . P, Kapil A, Chandra R etal,Antimicrobial resistance in 
Enterococcus faecalis in a tertiary care center of Northern 
India.Indian J Med Res 2003;118:25-28. 
33. Mohanty.S,Jose.S, Singhal. R, et al.Species prevalence and 
antimicrobial susceptibility of Enterococci isolated in a tertiary 
care hospital of north India. Southeast Asian J Trop Med Public 
Health,2005,36;962-965. 
34. Mohanty S, Dhawan B. GadepalliRS et al. Vancomycin resistant 
Enterococcus faecium Van A Phenotype: First documented 
isolation in India. Southeast Asian J Trop Med Public 
Health.2006; 37:(2)335-38.     
35. Murray BE, The life and times of Enterococcus. Clin Microbiol 
Rev 1990;3:46-65. 
36. Murray BE,Vancomycin Resistant Enterococci Am J Med 
1997;102:284-293. 
 
37. Perlada.E.D,Smulian,AG, Cushion.M.T et al,molecular 
epidemiology and antibiotic susceptibility of Enterococci in 
Cincinnati,Ohio:a prospective city wise study.J.Clin 
Microbiol.19997;35(9);2342-47 
38. Praharaj .I,Sujatha.S, Parija SC ,et al. Fatal meningitis caused by 
Vancomycin resistant Enterococci:Report of two cases from south 
India.Indian J Med Microbiol . 2012;30: (2) 242-245. 
39. Salem-Bekhit MM, Moussa IMI, MuharramMM,et al, Prevalence 
and antimicrobial resistance pattern of multidrug resistant 
Enterococci isolatyed from clinical specimens.Indian J Med 
Microbiol 2012;30 (1):44-51. 
40. Sharifi Y, Hasani  A, Ghotaslou R et al, Molecular screening of 
virulence genes in high level gentamicin resistant Enterococcus 
faecalis and Eenterococcus faecium isolated from clinical 
specimens in Northwest Iran,Indian J Med Microbiol 2012; 30 
(2):175-81. 
41. Suzanne M P, Trick W E, Tenovor F C et al.Comparison of PCR 
assay to culture for surveillance detection of Vancomycin 
Resistant Enterococci.J Clin Microbiol 2003;41: 10, 4805-08. 
42. Swenson JM, Clark NC, Ferraro MJ et al.Development of a 
standardized screening method for detection of Vncomycin 
Resistant Enterococci.J Clin Microbiol 1994;32;1700-4. 
43. Taneja N, Rani P,Emmanuel R,et al.Significance of Vancomycin 
resistant Enterococci from urinary specimens at a tertiary care 
center in northern India.Indian J Med Res 2004;119:727-4.  
44. Uttley.A.H, RC George, J.Naidoo, et al.High level Vancomycin 
Resistant Enterococci causing hospital infections.Epidemiol  
Infect.1989; 103:173-181. 
45. Versalovic.J. Manual of Clinical Microbiology. 10th ed.ASM 
Press, Washington,DC. 
46. V. Gupta,Singla. N,et al,Speciation and antimicrobial 
susceptibility pattern of Enterococci from tertary heath care center 
in north India,J Clin Diag Res2007;1: (5) ,32-5. 
47. Vittal.P.P, Rao.S.\,Parija SC,et al,Prevalence of unusual non 
faecial and  non faecium  Enterococci  and atypical varients of 
Enterococci,BMC Infect Dis 2005;5;14. 
48. Galle cuzon, Naas,f, Fortinneau.N,et al,Novel chromogenic 
medium for the detection of Enterococcus faecium and 
Enterococus faecalis. J.Clin Mirobiol2008;46 (&):2442-44. 
49. Roger .M,Faucher.MC,Forest.P,et al, Evaluation of VanA specific 
PCR assay for detection of vancomycin resistant Enterococcus 
faecium during a hospital outbreak,J.Clin 
Microbiol,1997;37(10)3348-9.   
50. Woodford N, Glypeptide Resistant Enterococci ; A decade of 
experience.J Med Microbiol 1998 ; 47(10):849-62. 
51. Yasliani.S, Mobarez.AM, Doust.R.H, et al.Linezolid, vancomycin 
resistant Enterococcus isolated from clinical samples in Tehran 
hospital.Indian J Med Scien2009;63(7):297-302. 
52. U. Patel. R,UhlJR,Hopkins MK, et al. Multiplex PCR detection of 
vanA,vanB,vanC-1and vanC2/3 genes in enterococci.JClin 
Microbiol1997;35(3)703-7. 
 
 
 
 
 
 
 
 
 
KEY TO MASTER CHART: 
IP-Inpatient 
M-Male patient 
F-Female patient 
Mch-Male child 
Fch-Female child 
UTI- Urinary tract infection 
PUO- Pyrexia of unknown origin 
FFE –Fever for evaluation 
CKD- Chonic kidney disease 
CKD-Tx –Renal transplant recipient 
CA- BR-Carcinoma bronchus 
Pseudo-cys – Pseudocyst of pancreas 
S- Susceptible       R-Resistant 
vanA – van A genotype VRE 
 
 PRH- prolonged hospitalization 
Abuse – broad spectrum antibiotic use 
ET- tube- Endotracheal tube  
S.NO AGE/SEX WARD RISK FACTORS SAMPLE ISOLATE ANTIBIOTIC SUSCEPTIBILITY VRE PHENOTYPE VRE GENOTYPE
A2 47/F S-IP PH,AB use pus E.faecalis R-all vanB
A4 39/F U-OP R-UTI,AB use urine E.faecalis R-all vanA vanA
A21 8/12Mch P-IP AGE stool E.faecium S-Gentamycin vanA vanA
A23 55/M M-OP R-UTI, PRH,AB use urine E.faecium R-all vanB
A29 55/M M-OP R-UTI, fever urine E.faecium S-Gentamycin vanB
B3 2/Mch ISP-IP AB use, HP urine E.faecium S-Streptomycin vanA vanA
B4 36/F U-OP Fever, AB use urine E.faecium S-Streptomycin vanA vanA
B6 38/M M-OP PRH urine E.faecium R-all vanB
B7 55/F U-OP AB use,DM urine E.faecium R-all vanA vanA
B64 72/F M-OP DM, R-UTI, HP urine E.faecium R-all vanA vanA
C27 45/M MGE-IP HP,AB use urine E.faecium S-Doxycycline vanA vanA
C52 8/Fch P-IP R-UTI,HP urine E.faecium S-Ampicillin vanA vanA
C61 32/M SGE-IP HP,AB use pus E.faecium S-Doxycycline and streptomycin vanA vanA
C92 28/F ENT-IP HP,AB use pus E.faecium S-Streptomycin vanB
UN1 58/M IMCU-IP DM, AB use, HP urine E.faecium S-Ampicillin,Doxycycline vanA vanA
UN7 55/M U-OP DM,R-UTI urine E.faecalis S-Streptomycin, Ampicilllin vanB
UN8 30/F RSRM-IP HP,AB use urine E.faecium S-Streptomycin, Ampicilllin vanB
4 42/M CM-IP ET tube, HP, AB use bronch. Secrt E.faecium S-Gentamycin vanB
9 52/M N-IP HMD,HP,AB use urine E.faecium S-Gentamycin vanB
24 60/F ICU-IP DM,R-UTI,HP,AB use urine E.faecium S-Ampicillin,Doxycycline vanB
S.no Age Sex OP/IP
Clinical 
diagnosis Specimen Isolate
Antibio
tic 
suscept
ibility  
Penicilli
n 
Ampi
cillin
Erythr
omycin
Ciprofl
oxacin
Doxyc
ycline HLS HLG
Teicoplan
in
Vancomyci
n
VRE screen 
agar
MIC-
Vancomyci
n
VRE-
Genotype
A2 47 F IP ulcer-leg Pus E.faecalis R R R R R R R R POS R vanA
A4 39 F OP UTI Urine E.faecalis R R R R R R R R POS R vanA
A5 55 F IP Bile E.faecium R R R R S S S S Neg
A6 2 Fch IP PUO Urine E.faecalis R S S S R S S Neg
A7 65 M IP PUO Urine E.faecium R R R S R R S S Neg
A8 37 M IP CKD Urine E.faecalis R S S S S R S S Neg
A13 7 Fch IP PUO Urine E.faecium R R S R R S S Neg
A14 60 M IP UTI Urine E.faecalis R S R R S S S S Neg
A18 33 F IP UTI Urine E.faecium R S S S S S S S Neg
A21 8M Mch IP AGE Feces E.faecium R R R R S R R POS R vanA
A22 21 M IP PUO Urine E.faecium R R R R R R S S Neg
A23 55 M OP UTI Urine E.faecium R R R R R R R R POS R vanA
A25 28 F OP UTI Urine E.faecalis R S S R S S S S Neg
A27 6 Mch IP PUO Blood E.dispar R R R R S S S S Neg
A28 19 F OP CKD Urine E.faecium R R R R S R S S Neg
A29 55 M OP UTI Urine E.faecium R R R R R S R R POS R vanA
A30 79 M IP UTI Urine E.faecalis R S R R R R S S Neg
A31 11M Mch OP PUO Urine E.faecalis R S R R S R S S Neg
A33 35 F OP UTI Urine E.faecalis R S R R S S S S Neg
A34 20 F IP PUO Urine E.faecalis R S R R S S S S Neg
A35 6 Fch OP PUO Urine E.faecalis R S R S S S S S Neg
A36 35 F IP UTI Urine E.faecalis R R R R R R S S Neg
A37 4 Fch IP PUO Urine E.faecalis R R R R R R S S Neg
A68 11 Fch IP PUO Urine E.faecium R R R S R R S S Neg
A69 80 F IP UTI Urine E.faecium R R R R R S S S Neg
A70 32 M OP UTI Urine E.faecalis R S R R S R S S Neg
A71 40 F IP UTI Urine E.faecium R R R R S R S S Neg
A72 8 Fch IP PUO Blood E.faecalis R S R R R S S S Neg
A73 47 M IP PUO Blood E.faecalis R S R R R S S S Neg
A83 30 M OP UTI Urine E.faecalis R S R R S S S S Neg
A88 21 M OP UTI Urine E.faecium R R R R R R R S POS S
A91 28 F IP UTI Urine E.faecalis R S R S R S S S Neg
A92 30 M IP UTI Urine E.faecalis S S R R S R S S Neg
A97 4 Mch IP PUO Urine E.faecalis S S R R S S S S Neg
3 27 F OP UTI Urine E.faecalis R S R R S S S S Neg
4 42 M IP CA-BR BR-SEC E.faecium R R R R R S R R POS R vanA
8 62 F IP PUO Urine E.faecalis R S R R R R S S Neg
9 52 M OP CKD Urine E.faecium R R R R R S R R POS R vanA
10 39 F OP UTI Urine E.faecium R S R S S S S S Neg
11 12 Mch OP UTI Urine E.faecalis R S R R R R S S Neg
13 22 Fch OP UTI Urine E.faecium R R R R S R S S Neg
22 13 F OP UTI Urine E.faecalis R S R R S S S S Neg
24 60 F IP DM Urine E.faecium R S S S S S R R POS R vanA
25 15 F OP UTI Urine E.feacium R R R S R R S S Neg
40 62 F IP LRI Urine E.faecalis R S R R S S S S Neg
43 32 M OP PUO Urine E.faecium R R R S S R S S Neg
44 31 F IP UTI Urine E.faecalis R S R R R R S S Neg
45 43 M IP DM-HD Feces E.faecium R R R R S R S S Neg
46 35 M IP HD-DM Feces E.faecium R S R R S S S S Neg
47 38 F OP PUO Urine E.faecalis R R R R S R S S Neg
48 32 M OP UTI Urine E.faecalis R S R R S S S S Neg
50 40 F OP PUO Urine E.faecalis R S R R S S S S Neg
51 49 F OP UTI Urine E.faecalis R S R R S S S S Neg
54 55 M OP PUO Urine E.faecalis R S R S S S S S Neg
55 58 F OP Urine E.faecalis R S R R S S S S Neg
57 37 F OP LRI Urine E.columbae R S S S S S R R POS
58 9 Fch OP UTI Urine E.faecium R R R R R S S S Neg
60 22 F OP UTI Urine E.faecalis R S R R S S S S Neg
61 65 F IP DM Urine E.faecalis R S R R S S S S Neg
X1 65 F IP DM-HT Urine E.faecalis R R R R S R S S Neg
X2 24 F IP PUO Urine E.faecalis R S R R R S S S Neg
X3 6M Mch IP PUO Blood E.faecalis R S R S S S Neg
X4 17 F OP PUO Urine E.faecium R R R S S S S S Neg
X5 23 F IP DLD Blood E.faecium R S R R S S R S S Neg
X7 37 F OP UTI Urine E.faecium R R R S S R S S Neg
X8 27 F IP CKD Urine E.cCPC PNSE2R S R R S R R R Neg
X9 10 Fch IP PUO Urine E.faecalis R S R R S S S S Neg
X10 55 M IP CKD-TX Urine E.faecalis R R R S R R S S Neg
X12 60 F OP VD Urine E.faecalis R R S R S R S S Neg
S3 7 Mch OP UTI Urine E.faecalis R S R R S S S S Neg
S6 18 F IP PUO Urine E.faecalis R S R R S S S S Neg
F1 69 F OP Urine E.faecium R S R R S R S S Neg
F3 8M Mch IP PUO Urine E.faecalis R S S S S S S Neg
UN1 58 M IP Urine E.faecium R S R S S S S S Neg
UN2 55 F IP DM-HD Urine E.faecalis R S R R S R R R POS R
UN3 40 F OP Urine E.faecium R S R R S R R R POS
UN5 31 M IP Feces E.faecalis R S R R S R S S Neg
UN7 55 M OP UTI Urine E.faecalis R S R R S R R R POS R vanA
UN8 30 F IP POST-OP LSCSUrine E.faecium R S R R S R R R POS S
S7 13 F OP PUO Blood E.faecalis R S R R R R S S Neg
S8 37 F OP Urine E.faecalis R S R S S S S S Neg
S9 63 F IP DM-HD Urine E.faecalis R S R R S S S S Neg
S10 15 F OP UTI Urine E.faecalis S S R R S S S S Neg
S11 63 M IP DM-LRI Urine E.faecalis S S R R S S S S Neg
B1 43 F IP DM-SEP Blood E.feacium R R R R R R S R R POS R vanA
B2 11m Mch OP PUO Urine E.faecalis R S S S S S Neg
B3 2 Mch IP PUO Urine E.faecium R R R S S R R R POS
B4 36 F OP UTI Urine E.faecium R R R R S R R R POS R vanA
B5 75 M IP POP-turp Urine E.faecium R R R R S R R R POS
B6 38 M OP UTI Urine E.faecium R R R R R R R R POS R vanA
B7 55 F OP UTI Urine E.faecium R R R R R R R R POS
B8 4 Fch IP PUO Urine E.faecalis R R R R S R S S Neg
B9 15 M OP PUO Urine E.faecalis R S R R R R S S Neg
B11 45 F OP PUO Urine E.faecalis R S R S S R S S Neg
B12 65 M IP jaundice Urine E.faecalis R R R R S R S S Neg
B13 2 F IP PUO Urine E.faecium R S S S S S S S Neg
B14 4 F IP PUO Urine E.faecalis R S S S S S Neg
B15 47 F IP DM Urine E.faecium R R R R S R S S Neg
B17 49 F IP acute abd Urine E.faecalis R S R S S S S S Neg
B18 6 Mch OP Urine E.faecalis R S R R S S S Neg
B19 58 F OP UTI Urine E.faecium R R R R S R S S Neg
B20 10 M OP UTI Urine E.faecalis R S R R S R S S Neg
B21 2 Mch IP PUO Blood E.columbae R S R S S S S Neg
B22 55 F IP UTI Urine E.faecium R R S R S R S S Neg
B23 22 M IP PUO Urine E.faecalis R S S S S S S S Neg
B24 48 F IP UTI Urine E.faecalis S S R S S S S S Neg
B25 40 F IP PUO Urine E.faecalis R R R S S S S S S Neg
B26 8 Mch IP PUO Urine E.faecium R S S S R S S Neg
B27 8 Mch OP Urine E.faecalis R S S S S S S Neg
B28 20 F IP MNG Urine E.faecalis R S S S S S S S Neg
B32 30 F IP UTI Urine E.faecalis R R S S R S S S Neg
B53 55 M OP UTI Urine E.faecalis R R R R S R S S Neg
B54 19 F OP Urine E.faecium R R R R S R S S Neg
B55 7 M OP PUO Urine E.faecalis R S S S S S Neg
B57 6M Mch IP PUO Urine E.faecalis R S R R R S S Neg
B60 52 M IP HD-DM Urine E.faecium R R R S R R S S Neg
B61 12 F IP PUO Urine E.faecalis R S R S S S S S Neg
B64 72 F IP UTI Urine E.faecium R R R R R R R R POS R vanA
B65 46 F OP UTI Urine E.faecium R R R R S R R S S Neg
B67 30 F OP PID Urine E.raffinosus R R S S R S S S Neg
B68 9 M IP PUO Urine E.raffinosus R S S R S S Neg
B69 30 M OP Urine E.faecalis R S R R S S S S Neg
B70 25 M OP UTI Urine E.faecalis R S S S S S S S Neg
B71 31 F IP CKD Urine E.faecalis R S R R S S S S Neg
B72 47 M IP HD-IE Blood E.faecalis R S R R S S S S Neg
B74 30 M OP UTI Urine E.faecium R S R S S R S S Neg
B75 8 Fch OP Urine E.faecalis R R R R S S Neg
B76 21 M IP PID Urine E.faecium R S R R S R S S Neg
B77 51 M IP ASCITIS Urine E.faecalis R R R R S R S S Neg
B80 1 Mch IP PUO Urine E.faecalis R S S S S S Neg
B90 50 F OP UTI Urine E.sulfurous R S S S S S S S Neg
B92 12 F OP PUO Urine E.faecalis R S S S R S S Neg
B96 30 F OP UTI Urine E.faecalis R R R S S R S S Neg
B97 64 F OP Urine E.faecalis R R R R S S S S Neg
B98 50 F OP Urine E.faecalis R R S S R S S S Neg
B99 30 M IP Urine E.faecium R S S R S R S S Neg
C3 47 M OP PUO Urine E.faecium R R R R R S S S Neg
C5 43 F OP PID Urine E.faecalis R S R R S S S S Neg
C6 53 M IP HD Urine E.faecalis R R R R R R S S Neg
C7 24 M OP UTI Urine E.faecalis R S R R S R S S Neg
C8 28 M IP HD Urine E.faecalis R S R S S S S S Neg
C9 34 M IP HYD Urine E.faecium R R R R R R S S Neg
C10 43 M IP DM- ULCER Pus E.faecium R R R R R R S S Neg
C12 32 M IP HD Blood E.faecalis S R R S S S S S Neg
C14 45 F OP Urine E.faecalis R R R S R S S S Neg
C15 56 M OP UTI Urine E.faecalis R R S S R S S S Neg
C17 32 F OP UTI Urine E.faecalis R R R R R R S S Neg
C18 12 Fch OP PUO Urine E.faecalis R S R S S S S S Neg
C19 6 Mch IP PUO Urine E.faecium R R R R R R S S Neg
C20 13 F OP UTI Urine E.faecalis R S R S S S S S Neg
C21 18 F OP Urine E.faecium R R R R S R S S Neg
C23 36 M IP ABSECC LLEGPus E.avium R R R S S R S S Neg
C24 43 F OP UTI Urine E.faecium R R R R R R S S Neg
C27 45 M IP LD Urine E.faecium R R R S R R R R POS
C30 34 F IP LRI Urine E.raffinosus R R R S R S S S Neg
C34 21 M OP UTI Urine E.faecalis R R R S R S S S Neg
C35 34 F IP UTI Urine E.faecalis R R R S R R S S Neg
C37 72 M OP PUO Urine E.faecium R R R R R R S S Neg
C38 44 F IP HD Urine E.faecalis S S R S R R S S Neg
C39 54 M OP Urine E.faecium R S R S R S S S Neg
C40 31 M IP Ulcer thigh Pus E.faecalis R S S S S S S S Neg
C41 22 M OP Urine E.durans S S S S S S S S Neg
C42 22 M OP UTI Urine E.faecalis R R R S R R S S Neg
C43 2 McH OP PUO Urine E.faecium R R R R R R S S Neg
C44 50 F IP FEVER Urine E.dispar R S R S R R S S Neg
C45 49 F OP UTI Urine E.faecium R R R R S S S S Neg
C46 53 F IP Urine E.faecalis R S R S S R S S Neg
C47 38 F OP UTI Urine E.faecalis R S R S R R S S Neg
C48 63 M OP CKD Urine E.faecium R R R S R R S S Neg
C49 37 F OP CKD Urine E.faecium R R R R R R S S Neg
C50 8M Fch IP PUO Urine E.faecium R R R R S R S S Neg
C51 17 M IP Urine E.raffinosus R R S S R S S S Neg
C52 8 Fch OP UTI Urine E.faecium R S S S R R R POS
C53 35 F OP UTI Urine E.faecalis R S R R S R S S Neg
C54 60 F IP UTI Urine E.faecium R R S R R R S S Neg
C55 43 F OP UTI Urine E.columbae R R R S R R S S Neg
C56 38 M IP HD Pus E.faecium R R R R S R S S Neg
C57 25 F OP UTI Urine E.hirae R S S S R S S Neg
C58 11 McH OP PUO Urine E.faecalis R S S S R S S Neg
C59 38 M IP HD/DM Urine E.faecium R R R S R R S S Neg
C60 3 MCh IP PUO Urine E.faecalis R S R S S R S S Neg
C61 32 M IP PSEUDOCYST PANCREASPus E.faecium R R R S S R R R POS R vanA
C62 36 F OP UTI Urine E.raffinosus R S S S S S S S Neg
C63 67 F IP CVA Urine E.columbae S S S S S S S S Neg
C64 43 F OP UTI Urine E.faecalis R S R S S R S S Neg
C65 10 Mch IP PUO Urine E.faecium R R R R S S S S Neg
C66 2 Fch OP UTI Urine E.hirae S S S R S S S S Neg
C67 21 F IP HD Urine E.faecalis R S R S S S S S Neg
C68 28 F OP UTI Urine E.faecium R R R S S R S S Neg
C69 3 Fch OP Urine E.faecalis S S S S S S S S Neg
C70 32 M IP Abd-wnd Pus E.mundtii S S R R S S S S S Neg
C71 26 M IP Renal Tx Blood E.faecium R R R S S S S S Neg
C72 67 F OP UTI Urine E.faecalis S S R S R S S S Neg
C73 60 F OP CKD Urine E.faecalis S S R S S S S S Neg
C74 28 F IP LSCS -pod Urine E.faecalis S S S S S S S S Neg
C75 7 Fch IP PUO Urine E.faecium R R S R S S S Neg
C76 4 Mch OP LRI Urine E.faecium R R R S R S S Neg
C77 30 F OP CKD Urine E.sulfurous S S S S S S S Neg
C78 4 Fch OP Fever Urine E.sulfurous R R R S S S S Neg
C79 3 Fch OP Fever Urine E.faecium R S S S R S S Neg
C80 36 M OP UTI Urine E.faecium R S R R S S S S Neg
C81 51 M IP PUD Urine E.faecalis R S R R S S S S Neg
C82 16 M OP UTI Urine E.faecium R R R R S R S S Neg
C83 33 M OP UTI Urine E.faecalis R S S S S S S S Neg
C84 84 F IP CVA Urine E.faecium R R R S R R S S Neg
C85 37 M IP CH-Ulcer leg Pus E.durans R S R S R R S S Neg
C86 45 F OP UTI Urine E.faecium S S S S S S S Neg
C87 10 Fch IP RHD Urine E.faecalis R S S R R S S Neg
C88 35 F OP UTI Urine E.faecalis R S S S S S S S Neg
C89 73 M IP PUD-Fever Urine E.faecium R R R R R R S S Neg
C90 6 Mch OP Fever Urine E.raffinosus R R R R S S S Neg
C91 18 M IP Epilepsy Urine E.faecalis R R S R S S S Neg
C92 28 F IP Ear dis Pus E.faecium R R R R S R R R POS R vanA
C93 25 M OP UTI Urine E.faecium R R R R R R S S Neg
C94 21 F OP UTI Urine E.faecium R S S S S S S S Neg
C95 4 Fch OP FEVER Urine E.sulfurous S S S S S S S Neg
C96 20 F IP DLD Urine E.faecium R R R S R S S Neg
C97 8 Mch OP FEVER Urine E.faecium R R S S S S S Neg
C98 37 F OP UTI Urine E.sulfurous R R S S R S S S Neg
C99 4Day Fch IP Sepsis Blood E.faecium R S R S S S S Neg
C100 40 F IP AGE Feces E.faecalis R S R S R R S S Neg
C101 27 F IP AGE Feces E.faecalis R S R S S R S S Neg
D1 43 M IP CH-Ulcer leg Pus E.asini R S R S S S S S Neg
D2 32 M OP FEVER Urine E.CDC PNS E2S S R S R R S S Neg
D3 14 M OP UTI Urine E.faecalis R S S S S S S S Neg
D4 36 F OP PID Urine E.faecalis R S R R S S S S Neg
D5 26 F OP UTI Urine E.CDC PNS E2R S S S S S S S Neg
D6 38 M OP CKD Urine E.sulfurous R S R S S R S S Neg
D7 34 M IP HD Blood E.faecium R S R R S R R R POS
D8 27 F OP FEVER Urine E.raffinosus R S S S S S S S Neg
D9 54 M IP PUD Urine E.raffinosus R S R S S S S S Neg
D10 67 M OP DM Urine E.faecalis R S R S S S S S Neg
D11 7 Mch OP PUO Urine E.asini R S S S S S Neg
D12 47 F OP  UTI Urine E.faecium R R R R R R S S Neg
D13 37 M IP CKD Urine E.raffinosus R R S S R S S S Neg
D14 49 F OP PUO Urine E.faecalis R S R R S S S S Neg
D16 9 Mch OP Urine E.faecium R R S R S S Neg
D17 43 F OP UTI Urine E.faecium R S R R R S S S Neg
DI8 32 M IP CKD Urine E.durans S S S S S S S S Neg
D21 28 M IP DM Urine E.faecium R S R R S R S S Neg

